<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK26471" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK26471/" /><meta name="ncbi_pagename" content="POLG-Related Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>POLG-Related Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="POLG-Related Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/03/01" /><meta name="citation_author" content="Bruce H Cohen" /><meta name="citation_author" content="Patrick F Chinnery" /><meta name="citation_author" content="William C Copeland" /><meta name="citation_pmid" content="20301791" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK26471/" /><meta name="citation_keywords" content="Alpers-Huttenlocher Syndrome (AHS)" /><meta name="citation_keywords" content="Ataxia Neuropathy Spectrum (ANS)" /><meta name="citation_keywords" content="Autosomal Recessive Progressive External Ophthalmoplegia (arPEO)" /><meta name="citation_keywords" content="Autosomal Dominant Progressive External Ophthalmoplegia (adPEO)" /><meta name="citation_keywords" content="Childhood Myocerebrohepatopathy Spectrum (MCHS)" /><meta name="citation_keywords" content="Myoclonic Epilepsy Myopathy Sensory Ataxia (MEMSA)" /><meta name="citation_keywords" content="DNA polymerase subunit gamma-1" /><meta name="citation_keywords" content="POLG" /><meta name="citation_keywords" content="POLG-Related Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="POLG-Related Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Bruce H Cohen" /><meta name="DC.Contributor" content="Patrick F Chinnery" /><meta name="DC.Contributor" content="William C Copeland" /><meta name="DC.Date" content="2018/03/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK26471/" /><meta name="description" content="POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood." /><meta name="og:title" content="POLG-Related Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK26471/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/alpers/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK26471/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8838E8E04032A100000000057F01E9.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK26471_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK26471_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pnpla6-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pol3-leuk/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK26471_"><span class="title" itemprop="name"><i>POLG</i>-Related Disorders</span></h1><p class="contrib-group"><span itemprop="author">Bruce H Cohen</span>, MD, <span itemprop="author">Patrick F Chinnery</span>, BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci, and <span itemprop="author">William C Copeland</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK26471_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK26471_ai__"><div class="contrib half_rhythm"><span itemprop="author">Bruce H Cohen</span>, MD<div class="affiliation small">NeuroDevelopmental Science Center<br />Children&#x02019;s Hospital Medical Center of Akron<br />Northeast Ohio Medical University<br />Akron, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.snerdlihcnorka@nehocb" class="oemail">gro.snerdlihcnorka@nehocb</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Patrick F Chinnery</span>, BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci<div class="affiliation small">Department of Clinical Neurosciences<br />University of Cambridge<br />Cambridge, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.mac.lhcsdem@52cfp" class="oemail">ku.ca.mac.lhcsdem@52cfp</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">William C Copeland</span>, PhD<div class="affiliation small">Mitochondrial DNA Replication Group<br />Genome Integrity and Structural Biology Laboratory<br />National Institute of Environmental Health Sciences / NIH<br />Research Triangle Park, North Carolina<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.shein@1nalepoc" class="oemail">vog.hin.shein@1nalepoc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 16, 2010</span>; Last Update: <span itemprop="dateModified">March 1, 2018</span>.</p><p><em>Estimated reading time: 44 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="alpers.Summary" itemprop="description"><h2 id="_alpers_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>POLG</i>-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have some, but not all, of the features of a given <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the <i>POLG</i>-related disorders ranges from infancy to late adulthood.</p><ul><li class="half_rhythm"><div>Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure.</div></li><li class="half_rhythm"><div>Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss.</div></li><li class="half_rhythm"><div>Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE).</div></li><li class="half_rhythm"><div>The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare.</div></li><li class="half_rhythm"><div>Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> arPEO at the onset develop other manifestations of <i>POLG</i>-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades.</div></li><li class="half_rhythm"><div>Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Establishing the diagnosis of a <i>POLG</i>-related disorder relies on clinical findings and identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>POLG</i> pathogenic variants for all phenotypes except adPEO, for which identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is diagnostic.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Clinical management is largely supportive and involves conventional approaches for associated complications including occupational, physical, and speech therapy; nutritional interventions; and standard respiratory support, treatment for liver failure and disorders of arousal and sleep, and management of seizures and movement disorders.</p><p><i>Prevention of secondary complications:</i> Dose reductions of medications metabolized by hepatic enzymes to avoid toxicity.</p><p><i>Surveillance:</i> Evaluations by a multidisciplinary team of health care providers based on clinical findings; monitoring of liver enzymes every two to four weeks after introduction of any new anticonvulsant.</p><p><i>Agents/circumstances to avoid:</i> Valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) because of the risk of precipitating and/or accelerating liver disease.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>The <i>POLG</i>-related disorders in the spectrum of AHS, MCHS, MEMSA, ANS, and arPEO are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Autosomal dominant PEO (adPEO) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. For autosomal recessive phenotypes: heterozygotes (carriers) are generally believed to be asymptomatic; the offspring of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> parents have a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being carriers, and a 25% chance of being unaffected and not carriers; <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk family members is possible if the pathogenic variants in the family are known. For the autosomal dominant <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>: most affected individuals have an affected parent; each child of an affected individual has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. For pregnancies at increased risk for all phenotypes, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> is possible if the pathogenic variant(s) in the family are known.</p></div></div><div id="alpers.GeneReview_Scope"><h2 id="_alpers_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="alpers.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpers.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLG-</i>Related Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_alpers.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Alpers-Huttenlocher syndrome (AHS)</div></li><li class="half_rhythm"><div>Childhood myocerebrohepatopathy spectrum (MCHS)</div></li><li class="half_rhythm"><div>Myoclonic epilepsy myopathy sensory ataxia (MEMSA)</div></li><li class="half_rhythm"><div>Ataxia neuropathy spectrum (ANS)</div></li><li class="half_rhythm"><div>Autosomal recessive progressive external ophthalmoplegia (arPEO)</div></li><li class="half_rhythm"><div>Autosomal dominant progressive external ophthalmoplegia (adPEO)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#alpers.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="alpers.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#alpers.Differential_Diagnosis">Differential Diagnosis</a><i>.</i></p></div></dd></dl></div></div></div></div><div id="alpers.Diagnosis"><h2 id="_alpers_Diagnosis_">Diagnosis</h2><div id="alpers.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>POLG</i>-related disorders comprise a continuum of overlapping phenotypes. A <i>POLG</i>-related disorder <b>should be suspected</b> in individuals with combinations of the following clinical features and laboratory findings.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Movement disorder (e.g., myoclonus, dysarthria, choreoathetosis, parkinsonism)</div></li><li class="half_rhythm"><div>Myopathy (e.g., ptosis, ophthalmoplegia, proximal &#x0003e; distal limb weakness with fatigue and exercise intolerance)</div></li><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>Peripheral neuropathy</div></li><li class="half_rhythm"><div>Episodic psychomotor regression</div></li><li class="half_rhythm"><div>Psychiatric illness (e.g., depression, mood disorder)</div></li><li class="half_rhythm"><div>Endocrinopathy (e.g., diabetes mellitus, premature ovarian failure)</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div>Liver dysfunction or failure, which may follow exposure to certain antiepileptic drugs. This could result in elevations in the liver enzymes ALT, AST, and GTT as well as synthetic liver dysfunction causing hypoglycemia, hyperammonemia, elevated glutamine, hyperbilirubinemia, prolonged bleeding times (INR, PT, PTT), hypoalbuminemia, and low cholesterol.</div></li><li class="half_rhythm"><div>Respiratory chain defect and/or a defect of mitochondrial (mt) DNA (depletion or multiple deletions). This could result in respiratory chain dysfunction, identified by either enzymatic assays or polarographic assays. Depletion of mtDNA can be measured by comparing the value of mtDNA content in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissue (e.g., liver) with the nuclear DNA content. The use of <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> or long-range <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> of the mtDNA can detect deletions or multiple deletions in some individuals. Note: Biochemical findings on muscle biopsy can be normal, and normal respiratory chain function or absence of mtDNA depletion should not rule out consideration of a <i>POLG</i>-related disorder.</div></li><li class="half_rhythm"><div>Cerebrospinal fluid (CSF) protein is generally elevated in individuals with Alpers-Huttenlocher syndrome (AHS).</div></li></ul><p><b>Radiographic features</b></p><ul><li class="half_rhythm"><div>Brain computerized tomography (CT) or magnetic resonance imaging (MRI) may be normal early in the course of AHS.</div></li><li class="half_rhythm"><div>As the illness evolves neuroimaging shows gliosis (initially more pronounced in the occipital lobe regions) and generalized brain atrophy.</div></li></ul></div><div id="alpers.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>Clinical diagnostic criteria do not exist. The diagnosis of most <i>POLG-</i>related disorders <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <b><a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a></b> pathogenic variants in <i>POLG</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK26471/table/alpers.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figalpersTmoleculargenetictestingused" rid-ob="figobalpersTmoleculargenetictestingused">Table 1</a>). The diagnosis of adPEO <b>is established</b> in a proband by identification of a <b><a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a></b> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>POLG</i> by molecular genetic testing (see <a class="figpopup" href="/books/NBK26471/table/alpers.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figalpersTmoleculargenetictestingused" rid-ob="figobalpersTmoleculargenetictestingused">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>POLG</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Sequence analysis of <i>TWNK</i> (formerly <i>C10orf2</i> or <i>PEO1</i>) may be considered in persons with a suspected <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <i>POLG</i>-related disorder but in whom only one <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified by single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing, to investigate the possibility of <a class="def" href="/books/n/gene/glossary/def-item/digenic/">digenic</a> inheritance (see <a href="#alpers.Differential_Diagnosis">Differential Diagnosis</a>). Digenic inheritance has been reported in autosomal recessive progressive external ophthalmoplegia (arPEO) in a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case with pathogenic variants in <i>POLG</i> and <i>TWNK</i> [<a class="bk_pop" href="#alpers.REF.van_goethem.2003a.175">Van Goethem et al 2003a</a>].</div><div class="half_rhythm">Note: In the 5% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases of PEO in which only a single <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, it can be difficult to distinguish between <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>POLG</i> pathogenic variant.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>POLG</i>, <i>TWNK</i> (formerly <i>C10orf2</i> or <i>PEO1</i>), and other genes of interest (see <a href="#alpers.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, mtDNA sequencing, and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="alpers.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>POLG</i>-Related Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLG</i></td><td headers="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;95%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_alpers.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Three alleles reported&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alpers.TF.1.1"><p class="no_margin">See <a href="/books/NBK26471/#alpers.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="alpers.TF.1.2"><p class="no_margin">See <a href="#alpers.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="alpers.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="alpers.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#alpers.REF.ashley.2008.2496">Ashley et al [2008]</a>, <a class="bk_pop" href="#alpers.REF.hunter.2011.311">Hunter et al [2011]</a></p></div></dd><dt>5. </dt><dd><div id="alpers.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="alpers.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#alpers.REF.compton.2011.104">Compton et al [2011]</a>, <a class="bk_pop" href="#alpers.REF.naess.2012.67">Naess et al [2012]</a>, <a class="bk_pop" href="#alpers.REF.rouzier.2014.542">Rouzier et al [2014]</a></p></div></dd></dl></div></div></div></div></div><div id="alpers.Clinical_Characteristics"><h2 id="_alpers_Clinical_Characteristics_">Clinical Characteristics</h2><div id="alpers.Clinical_Description"><h3>Clinical Description</h3><p><i>POLG</i>-related disorders comprise a continuum of broad and overlapping phenotypes that can be distinct clinical entities or consist of a spectrum of overlapping phenotypes. Presentations within a given family are usually similar. Although almost any organ system can be involved, evidence to date suggests that diabetes and cardiomyopathy are not common in <i>POLG</i>-related disorders, distinguishing them from other multisystem mitochondrial diseases.</p><p><a class="figpopup" href="/books/NBK26471/table/alpers.T.clinical_findings_in_polgrelate/?report=objectonly" target="object" rid-figpopup="figalpersTclinicalfindingsinpolgrelate" rid-ob="figobalpersTclinicalfindingsinpolgrelate">Table 2</a> summarizes the clinical findings in <i>POLG</i>-related disorders. Because the description of new <i>POLG</i> pathogenic variants is ongoing, knowledge of their associated phenotypes continues to evolve.</p><div id="alpers.T.clinical_findings_in_polgrelate" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical Findings in <i>POLG</i>-Related Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.T.clinical_findings_in_polgrelate/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.T.clinical_findings_in_polgrelate_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Finding</th><th id="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation</th><th id="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Notes/References</th></tr></thead><tbody><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Cortical</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.nguyen.2006.108">Nguyen et al [2006]</a>, <a class="bk_pop" href="#alpers.REF.wong.2008.e150">Wong et al [2008]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Developmental delay</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Seizure disorder</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myoclonus</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in children [<a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>] &#x00026; adults w/ataxia [<a class="bk_pop" href="#alpers.REF.van_goethem.2004.1251">Van Goethem et al 2004</a>, <a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al 2005</a>, <a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Focal motor seizures</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Generalized seizures</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a>, <a class="bk_pop" href="#alpers.REF.winterthun.2005.1204">Winterthun et al [2005]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Status epilepticus</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">"Cerebrovascular" involvement</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Migraine</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May precede other features by many years [<a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al 2005</a>, <a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke-like episodes</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually asymptomatic in children, diagnosed on imaging [<a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Extrapyramidal movement disorder</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parkinsonism</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Responds to levodopa [<a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al 2004</a>, <a class="bk_pop" href="#alpers.REF.mancuso.2004.1777">Mancuso et al 2004</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Chorea</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Peripheral neuropathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sensory neuronopathy / ganglionopathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Corresponds to the acronym SANDO [<a class="bk_pop" href="#alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</a>]; profound sensory ataxia</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Axonal sensorimotor neuropathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.davidzon.2006.859">Davidzon et al [2006]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar involvement</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.van_goethem.2004.1251">Van Goethem et al [2004]</a>, <a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a>, <a class="bk_pop" href="#alpers.REF.winterthun.2005.1204">Winterthun et al [2005]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Psychiatric illness</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Depression</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al [2004]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Psychosis</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dementia</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.van_goethem.2004.1251">Van Goethem et al [2004]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Special sensory</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sensorineural deafness</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.di_fonzo.2003.498">Di Fonzo et al [2003]</a>, <a class="bk_pop" href="#alpers.REF.filosto.2003.1279">Filosto et al [2003]</a>, <a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Retinopathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.di_fonzo.2003.498">Di Fonzo et al [2003]</a>, <a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al [2004]</a>, <a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ocular</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cataract</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.bekheirnia.2012.209">Bekheirnia et al [2012]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Gastrointestinal system</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver failure</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spontaneous or precipitated by sodium valproate in children [<a class="bk_pop" href="#alpers.REF.naviaux.2004.706">Naviaux &#x00026; Nguyen 2004</a>, <a class="bk_pop" href="#alpers.REF.nguyen.2005.1493">Nguyen et al 2005</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>]; also in adults w/ataxia [<a class="bk_pop" href="#alpers.REF.van_goethem.2004.1251">Van Goethem et al 2004</a>, <a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gastrointestinal dysmotility</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.filosto.2003.1279">Filosto et al [2003]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Myopathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ptosis &#x00026; external ophthalmoplegia</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May be <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> ptosis [<a class="bk_pop" href="#alpers.REF.luoma.2005.1907">Luoma et al 2005</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Proximal myopathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myopathy reported [<a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>]</td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Exercise intolerance</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.di_fonzo.2003.498">Di Fonzo et al [2003]</a>, <a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al [2004]</a>, <a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Endocrine/gonadal system</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diabetes mellitus</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Primary ovarian failure</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al [2004]</a>, <a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Ovarian dysgenesis</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.bekheirnia.2012.209">Bekheirnia et al [2012]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Primary testicular failure</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.filosto.2003.1279">Filosto et al [2003]</a></td></tr><tr><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiomyopathy</td><td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.van_goethem.2004.1251">Van Goethem et al [2004]</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Reproduced and modified from <a class="bk_pop" href="#alpers.REF.hudson.2006.r244">Hudson &#x00026; Chinnery [2006]</a></p></div></dd></dl></div></div></div><p>Although some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals present with a classic syndrome, many have some, but not all, of the features of one or more of the recognized phenotypes. <i>POLG</i>-related disorders can therefore be considered as an overlapping spectrum of disease presenting from early childhood to late adulthood. The age of onset broadly correlates with the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><div id="alpers.AlpersHuttenlocher_Syndrome_AHS"><h4>Alpers-Huttenlocher Syndrome (AHS)</h4><p>AHS, one of the most severe phenotypic manifestations in the spectrum of <i>POLG</i>-related disorders, is characterized by a progressive and ultimately severe encephalopathy with intractable epilepsy, neuropathy, and hepatic failure. While AHS is usually fatal, the age of onset, rate of neurologic degeneration, presence of hepatic failure, and age of death vary [<a class="bk_pop" href="#alpers.REF.davidzon.2006.859">Davidzon et al 2006</a>, <a class="bk_pop" href="#alpers.REF.nguyen.2006.108">Nguyen et al 2006</a>, <a class="bk_pop" href="#alpers.REF.wong.2008.e150">Wong et al 2008</a>, <a class="bk_pop" href="#alpers.REF.cohen.2010.364">Cohen &#x00026; Naviaux 2010</a>, <a class="bk_pop" href="#alpers.REF.saneto.2013.167">Saneto et al 2013</a>].</p><p>Children with AHS appear healthy at birth and may develop normally over the first few weeks to years of life. Some have variable degrees of developmental delay prior to the initial recognition of neurodegeneration. Onset is usually between ages two and four years, but ranges from one month to 36 years.</p><p><b>Seizures</b> are the first sign of AHS in about 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children. Seizures may be simple focal, primary generalized, or myoclonic. The most common early seizure types are partial seizures and secondary generalized tonic-clonic seizures. In some children the first seizure presents with status epilepticus. EEG findings include high-amplitude slow activity with smaller polyspikes or intermittent continuous spike-wave activity [<a class="bk_pop" href="#alpers.REF.w_rle.1998.63">W&#x000f6;rle et al 1998</a>].</p><p>In some instances the first seizure type is epilepsia partialis continua (EPC), a classic seizure type in which the motor seizure involves only one portion of the body (e.g., a limb) with a constant and repetitive myoclonic jerking, continuing for hours or days with or without dramatic effects on consciousness. EPC is not always apparent as an abnormality on EEG and can be mistaken for a conversion reaction. EEG may be normal or show only focal slowing of the background rhythm.</p><p>Over time the seizures can evolve into a complex epileptic disorder such as focal status epilepticus, epilepsia partialis continua, or multifocal myoclonic epilepsy [<a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>, <a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>].</p><p>In some children the seizures are initially controllable with usual dosages of anticonvulsants; in others the seizures, such as EPC, are refractory from the onset. Over time the seizures become increasingly resistant to anticonvulsant therapy. See <a href="#alpers.Treatment_of_Manifestations">Treatment of Manifestations</a> for further information about management of seizures. Of note, valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) can precipitate the liver dysfunction in AHS and should be avoided [<a class="bk_pop" href="#alpers.REF.saneto.2010.140">Saneto et al 2010</a>].</p><p><b>Headaches,</b> another common first presenting symptom, are typically associated with visual sensations or visual auras that reflect early occipital lobe dysfunction [<a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al 2005</a>, <a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>]. Stroke and stroke-like episodes may occur in this disorder as well [<a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>].</p><p><b>Movement disorders,</b> primarily myoclonus and choreoathetosis, are common [<a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>]. Myoclonus can be difficult to distinguish from myoclonic seizures and EPC. Palatal myoclonus resulting from involvement of the inferior olivary nuclei can be seen as well. Some develop parkinsonism, which may temporarily respond to levodopa [<a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al 2004</a>, <a class="bk_pop" href="#alpers.REF.mancuso.2004.1777">Mancuso et al 2004</a>].</p><p><b>Neuropathy and ataxia</b> develop in all persons with AHS unless the disease process is so rapid that it results in early death. All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors.</p><p><b>Areflexia</b> (resulting from neuropathy) and <b>hypotonia</b> (possibly the result of generalized weakness as part of systemic illness or pyramidal or extrapyramidal dysfunction) are often both present early in the disease course.</p><p><b>Episodic psychomotor regression</b> is variably present at the time of initial consideration of the diagnosis. The major motor manifestation is a progressive spastic paraparesis resulting from progressive loss of cortical neuronal function. Progressive spasticity occurs universally; has variable onset, and evolves over months to years.</p><p><b>Loss of cognitive function</b> occurs throughout the course of the disease, but the time of onset and rate of progression are variable. Significant sudden or rapid regression is often seen during infectious illnesses. The clinical manifestations may include somnolence, loss of concentration, loss of language skills (both receptive and expressive), irritability with loss of normal emotional responses, and memory deficits. In addition to the dementia caused by loss of brain tissue and the refractory seizures, the high dosages of medication used to treat those seizures can lead to significant cognitive impairment. The degree of dementia is often difficult to assess because of the frequent seizures and high therapeutic doses of anticonvulsants, which can cloud the sensorium.</p><p><b>Cortical visual loss</b> leading to blindness may appear months to years after the onset of other neurologic manifestations. Retinopathy (<a href="/books/n/gene/rp-overview/">retinitis pigmentosa</a>) may also play a less important role in vision loss [<a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al 2005</a>]. Hearing loss is variable [<a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al 2005</a>, <a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al 2006</a>].</p><p><b>Liver involvement</b> can progress rapidly to end-stage liver failure within a few months, although this is highly variable. End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia. Rapid onset of liver failure is described when valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) have been used to treat seizures, although the introduction of other anticonvulsants, including phenytoin, may also play a role in onset of hepatic failure. Longer survival in AHS through improved care for those with profound dementia and motor dysfunction results in the occurrence of late-onset hepatic involvement in a higher percentage of children with AHS now than previously noted.</p><p><b>Disease progression</b> is variable in timing and rapidity. Loss of neurologic function culminates in dementia, spastic quadriparesis from corticospinal tract involvement, visual loss, and death. The rate of neurodegeneration varies and is marked by periods of stability. The typical life expectancy from onset of first symptoms ranges from three months to 12 years.</p><p><b>Neuroimaging.</b> CT or MRI of the brain may be normal early in the course of AHS. As the illness evolves neuroimaging shows gliosis (initially more pronounced in the occipital lobe regions) and generalized brain atrophy.</p><p>FLAIR and T<sub>2</sub>-weighted sequence images demonstrate high signal intensity in deep gray matter nuclei, especially in the thalamus and cerebellum [<a class="bk_pop" href="#alpers.REF.smith.1996.235">Smith et al 1996</a>]. Lesions described in the inferior olivary nuclei may also be a part of AHS and are associated with palatal myoclonus.</p><p><b>Pathophysiology.</b> Depletion of mtDNA develops in clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues causing a mitochondrial oxidative-phosphorylation defect resulting in the clinical findings of AHS.</p><p><b>Brain.</b> The gross appearance of the brain varies from normal to severe atrophy, depending on the state of disease progression. The central nervous system regions affected in AHS are the same as those affected by Leigh syndrome but typically evolve in the reverse order. For example, in AHS the gliosis is most severe and occurs earliest in the cerebral cortex, followed by the cerebellum, basal ganglia, and brain stem. Involved regions demonstrate neuronal degeneration, characteristic spongiform or microcystic degeneration, and &#x02013; as seen in Leigh syndrome &#x02013; gliosis, necrosis, and capillary proliferation. The cortical ribbon shows patchy lesions, but the calcarine cortex, which is characteristically involved early in the course of the disease, is usually narrowed, granular, and discolored.</p><p>Microscopic abnormalities, present throughout the cerebral cortex, evolve as the disease progresses. Early in the course of the disease spongiosis, astrocytosis, and neuronal loss are prevalent in the superficial cortex. Later the deeper laminae are affected. In the most advanced stage the entire cortex becomes a thin dense gliotic scar. Usually the striate cortex is the most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> part of the brain followed by the thalamus, hippocampus, and cerebellum. These pathologic features differ from those resulting from hypoxic injury, recurrent seizures, or other causes of hepatic failure.</p><p><b>Liver.</b> Liver histology may demonstrate macro- and microvesicular steatosis, centrilobular necrosis, disorganization of the normal lobular architecture, hepatocyte loss with or without bridging fibrosis or cirrhosis, regenerative nodules, bile duct proliferation, or mitochondrial proliferation with a vivid eosinophilic cytoplasm (oncocytic change). Florid cirrhosis occurs late in the disease. This pathology differs from that seen in chemically induced or toxic hepatopathies.</p></div><div id="alpers.Childhood_Myocerebrohepatopathy_S"><h4>Childhood Myocerebrohepatopathy Spectrum (MCHS)</h4><p>MCHS presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other features of a mitochondrial disorder that may be present include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Seizures are not present, at least early in the disease course [<a class="bk_pop" href="#alpers.REF.wong.2008.e150">Wong et al 2008</a>].</p></div><div id="alpers.Myoclonic_Epilepsy_Myopathy_Senso"><h4>Myoclonic Epilepsy Myopathy Sensory Ataxia (MEMSA)</h4><p>Previously referred to as spinocerebellar ataxia with epilepsy (SCAE), MEMSA now describes the spectrum of disorders with myopathy, epilepsy, and ataxia without ophthalmoplegia. Cerebellar ataxia, generally the first sign, begins in young adulthood as a subclinical sensory polyneuropathy. Epilepsy develops in later years, often beginning focally in the right arm and then spreading to become generalized. The seizures may be refractory to conventional therapy, including anesthesia. Recurrent bouts of seizure activity are accompanied by progressive interictal encephalopathy. The myopathy in MEMSA may be distal or proximal, and, as in the other <i>POLG</i>-related disorders, it also may present as exercise intolerance.</p></div><div id="alpers.Ataxia_Neuropathy_Spectrum_ANS"><h4>Ataxia Neuropathy Spectrum (ANS)</h4><p>ANS includes mitochondrial recessive ataxia syndrome (MIRAS) and a separate entity known as sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO) [<a class="bk_pop" href="#alpers.REF.fadic.1997.239">Fadic et al 1997</a>]. ANS is characterized by ataxia, neuropathy, and (in most but not all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) an encephalopathy with seizures. The encephalopathy is similar to that seen in AHS but tends to be more slowly progressive and can even be mild. The neuropathy may be sensory, motor, or mixed and can be severe enough to contribute to ataxia &#x02013; so-called sensory ataxia. About 25% of affected individuals have cramps, but clinical myopathy is rare.</p><p>Other features may include myoclonus, blindness, and liver dysfunction [<a class="bk_pop" href="#alpers.REF.wong.2008.e150">Wong et al 2008</a>]. Liver findings range from no dysfunction to elevated enzymes and mild synthetic dysfunction, to (in some cases) florid liver failure [<a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>, <a class="bk_pop" href="#alpers.REF.wong.2008.e150">Wong et al 2008</a>]. Psychiatric illness including depression is common. Headache, generally migrainous, is also common and may precede other symptoms by many years.</p><p>Although muscle pathology may show COX-negative fibers, there may be no pathologic findings.</p></div><div id="alpers.Autosomal_Recessive_Progressive_E"><h4>Autosomal Recessive Progressive External Ophthalmoplegia (arPEO)</h4><p>Progressive PEO without systemic involvement is the hallmark of arPEO. Caution needs to be exercised, however, when making the diagnosis of arPEO, as some <i>POLG</i> pathogenic variants associated with arPEO are also associated with ANS and other <i>POLG</i>-related disorders with systemic involvement. Thus, many individuals who have no other clinical findings at the time of diagnosis with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> arPEO develop other manifestations of <i>POLG</i>-related disorders over subsequent years or decades [<a class="bk_pop" href="#alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</a>, <a class="bk_pop" href="#alpers.REF.lamantea.2002.211">Lamantea et al 2002</a>, <a class="bk_pop" href="#alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</a>]. In the past these findings were designated "PEO+" or "PEO+ disease."</p></div><div id="alpers.Autosomal_Dominant_Progressive_Ex"><h4>Autosomal Dominant Progressive External Ophthalmoplegia (adPEO)</h4><p>The universal manifestation of this adult-onset disorder is progressive weakness of the extraocular eye muscles resulting in ptosis and strabismus [<a class="bk_pop" href="#alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</a>]. A generalized myopathy is present in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, leading to early fatigue and exercise intolerance. Some affected individuals (in what has been called "chronic progressive external ophthalmoplegia plus," or CPEO+) have variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts [<a class="bk_pop" href="#alpers.REF.luoma.2004.875">Luoma et al 2004</a>, <a class="bk_pop" href="#alpers.REF.pagnamenta.2006.2467">Pagnamenta et al 2006</a>]. Cardiomyopathy and gastrointestinal dysmotility are less common.</p></div></div><div id="alpers.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations are not possible because all combinations of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> type and location have been associated with the entire phenotypic spectrum and with both <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance.</p></div><div id="alpers.Nomenclature"><h3>Nomenclature</h3><p>Alpers-Huttenlocher syndrome (AHS) is named after Bernard Alpers, who first described the disease in 1931, and Peter Huttenlocher, who with his colleagues described the associated liver disease and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> [<a class="bk_pop" href="#alpers.REF.huttenlocher.1976.186">Huttenlocher et al 1976</a>].</p><p>In the older literature, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> progressive external ophthalmoplegia (adPEO) associated with additional findings was labeled "chronic progressive external ophthalmoplegia plus" (CPEO+).</p></div><div id="alpers.Prevalence"><h3>Prevalence</h3><p>AHS is reported to affect approximately one in 51,000 people [<a class="bk_pop" href="#alpers.REF.darin.2001.377">Darin et al 2001</a>]; however, because some pathogenic variants are found at high frequencies in certain populations and founder variants occur in some populations, the frequency may vary greatly by ethnicity.</p><p>The sum frequency of the most common <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> pathogenic variants can be used to estimate disease frequency at 1:10,000:</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.Ala467Thr</a>. ~0.2%-0.6% (up to 1% in Norway)</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.[Trp748Ser;Glu1143Gly]</a>. ~0.1%-0.8%</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.Gly848Ser</a>. ~0.05%-0.1%</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.Pro587Leu</a>. ~0.05%</div></li></ul><p>Pathogenic variants in <i>POLG</i>, identified in nearly 50% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> PEO (adPEO) in one study [<a class="bk_pop" href="#alpers.REF.lamantea.2002.211">Lamantea et al 2002</a>], may be the most frequent cause of adPEO.</p></div></div><div id="alpers.Genetically_Related_Allelic_Disor"><h2 id="_alpers_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>Because the description of new <i>POLG</i> pathogenic variants is ongoing, knowledge of their associated phenotypes continues to evolve. <i>POLG</i> pathogenic variants have been shown to be associated with Charcot-Marie-Tooth neuropathy type 2 (see <a href="/books/n/gene/cmt/">CMT Overview</a>) [<a class="bk_pop" href="#alpers.REF.harrower.2008.133">Harrower et al 2008</a>], <a href="/books/n/gene/narp/">Leigh syndrome</a> [<a class="bk_pop" href="#alpers.REF.naess.2009.484">Naess et al 2009</a>, <a class="bk_pop" href="#alpers.REF.taanman.2009.248">Taanman et al 2009</a>], and a MNGIE-like illness [<a class="bk_pop" href="#alpers.REF.tang.2012.862">Tang et al 2012</a>] &#x02013; diseases that are generally associated with defects in other genes.</p></div><div id="alpers.Differential_Diagnosis"><h2 id="_alpers_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Epilepsia partialis continua</b> (EPC), seen in Alpers-Huttenlocher syndrome, can result from structural brain lesions (e.g., stroke, neoplasia, cortical dysplasia, traumatic lesion). EPC has also been described in individuals with <i>COQ8A</i>-related <a href="/books/n/gene/coq10-def/">primary coenzyme Q<sub>10</sub> deficiency</a> [<a class="bk_pop" href="#alpers.REF.hikmat.2016.1188">Hikmat et al 2016</a>], NADH coenzyme Q reductase deficiency [<a class="bk_pop" href="#alpers.REF.antozzi.1995.152">Antozzi et al 1995</a>], <a href="/books/n/gene/merrf/">MERRF</a>, <a href="/books/n/gene/narp/">Leigh syndrome</a> [<a class="bk_pop" href="#alpers.REF.mameni_kien_.2017.74">Mameni&#x00161;kien&#x00117; &#x00026; Wolf 2017</a>], and nonketotic hyperglycemia [<a class="bk_pop" href="#alpers.REF.mameni_kien_.2017.74">Mameni&#x00161;kien&#x00117; &#x00026; Wolf 2017</a>]. Recently, <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>TBC1D24</i> pathogenic variants were identified in an individual with EPC [<a class="bk_pop" href="#alpers.REF.zhou.2018.750">Zhou et al 2018</a>].</p><div id="alpers.Mitochondrial_DNA_Depletion_MDD_D"><h3>Mitochondrial DNA Depletion (MDD) Disorders</h3><p>MDD disorders may affect either a specific tissue (most commonly muscle or liver) or multiple organs, including the heart, brain, and kidney. MDD disorders need to be distinguished from the disorders of mtDNA mutation, <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>, or <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>).</p><p>Mitocondrial DNA depletion syndromes, a genetically and clinically heterogeneous group of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorders, are characterized by a severe reduction in mtDNA content leading to impaired energy production in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues and organs.</p><p>Mitochondrial DNA depletion syndromes occur as a result of defects in mtDNA maintenance caused by pathogenic variants in nuclear genes that function in either mitochondrial nucleotide synthesis (e.g., <i>TK2</i>, <i>SUCLA2</i>, <i>SUCLG1</i>, <i>RRM2B</i>, <i>DGUOK</i>, and <i>TYMP</i>) or mtDNA replication (e.g., <i>POLG</i> and <i>TWNK</i>).</p><p>Mitochondrial DNA depletion syndromes are phenotypically classified into myopathic, encephalomyopathic, hepatocerebral, and neurogastrointestinal forms (see <a class="figpopup" href="/books/NBK26471/table/alpers.T.mitochondrial_dna_depletion_syn/?report=objectonly" target="object" rid-figpopup="figalpersTmitochondrialdnadepletionsyn" rid-ob="figobalpersTmitochondrialdnadepletionsyn">Table 3</a>) [<a class="bk_pop" href="#alpers.REF.elhattab.2013.186">El-Hattab &#x00026; Scaglia 2013</a>].</p><ul><li class="half_rhythm"><div><b>Myopathic forms</b> present in infancy or early childhood with hypotonia, proximal muscle weakness, and feeding difficulty. Cognition is usually spared. Typically, there is rapid progression of muscle weakness with respiratory failure and death within a few years of onset.</div></li><li class="half_rhythm"><div><b>Encephalomyopathic mtDNA depletion syndromes</b> present in infancy with hypotonia and global developmental delay. Depending on the underlying defect, other features including deafness, movement disorders, Leigh like syndrome, and renal disease can be observed.</div></li><li class="half_rhythm"><div><b>Hepatocerebral forms</b> present with early-onset liver dysfunction and neurologic involvement, including developmental delay, abnormal eye movements, and peripheral neuropathy.</div></li><li class="half_rhythm"><div><b>Neurogastrointestinal forms,</b> the prototype of which is mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease, present in adolescence to early adulthood with progressive gastrointestinal dysmotility, cachexia, and peripheral neuropathy.</div></li></ul><p><a class="figpopup" href="/books/NBK26471/table/alpers.T.mitochondrial_dna_depletion_syn/?report=objectonly" target="object" rid-figpopup="figalpersTmitochondrialdnadepletionsyn" rid-ob="figobalpersTmitochondrialdnadepletionsyn">Table 3</a> classifies the mtDNA depletion syndromes by phenotypic category and associated genes.</p><p>Note: For some of the genes (<i>POLG</i> and <i>TWNK</i>), other phenotypes not associated with mtDNA depletion with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or recessive inheritance have been reported.</p><div id="alpers.T.mitochondrial_dna_depletion_syn" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Mitochondrial DNA Depletion Syndromes</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.T.mitochondrial_dna_depletion_syn/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.T.mitochondrial_dna_depletion_syn_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype&#x000a0;<sup>1</sup></th><th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial DNA Depletion Syndrome #, Type&#x000a0;<sup>2</sup></th><th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Function of Gene Product</th></tr></thead><tbody><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Hepatocerebral</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DGUOK</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3, hepatocerebral type</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>POLG</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4A, Alpers type<br />(<i>POLG</i>-related disorders)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">mtDNA replication</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>MPV17</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6, hepatocerebral type<br />(<a href="/books/n/gene/mpv17-mtdep/"><i>MPV17</i>-related hepatocerebral mtDNA depletion syndrome</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>TWNK</i> (<i>C10orf2</i>, <i>PEO1</i>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7, hepatocerebral type<br />(OMIM <a href="http://omim.org/entry/271245" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">271245</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">mtDNA replication</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><i>TFAM</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15, hepatocerebral type<br />(OMIM <a href="https://omim.org/entry/617156" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617156</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a></td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Encephalomyopathic</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SUCLA2</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5, encephalomyopathic type w/ methylmalonic aciduria<br />(<a href="/books/n/gene/sucla2-def/"><i>SUCLA2</i>-related mtDNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>FBXL4</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13, encephalomyopathic type<br />(<a href="/books/n/gene/fbxl4-mtddepl/"><i>FBXL4</i>-related encephalomyopathic mtDNA depletion syndrome</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">F-box and leucine-rich repeat protein 4</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SUCLG1</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9, encephalomyopathic type w/ methylmalonic aciduria<br />(<a href="/books/n/gene/suclg1-mtddepl/"><i>SUCLG1</i>-related mtDNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>RRM2B</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8A, encephalomyopathic type w/ renal tubulopathy<br />(<a href="/books/n/gene/rrm2b-mtddepl/"><i>RRM2B</i>-related mitochondrial disease</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>OPA1</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14, encephalocardiomyopathic type<br />(OMIM <a href="http://omim.org/entry/616896" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616896</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial dynamics</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>ABAT</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Encephalomyopathic type<br />(OMIM <a href="http://omim.org/entry/613163" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613163</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4-aminobutyrate aminotransferase</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Neurogastrointestinal</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TYMP</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1, MNGIE type<br />(<a href="/books/n/gene/mngie/">mitochondrial neurogastrointestinal encephalopathy disease</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thymidine phosphorylase, dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>POLG</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4B, MNGIE type<br />(<i>POLG</i>-related disorders)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">mtDNA replication</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>RRM2B</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8B, MNGIE type<br />(<a href="/books/n/gene/rrm2b-mtddepl/"><i>RRM2B</i>-related mitochondrial disease</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Myopathic</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TK2</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2, myopathic type<br />(<a href="/books/n/gene/tk2-mtddepl/"><i>TK2</i>-related mtDNA depletion syndrome, myopathic form</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">dNTP pools</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>AGK</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10, cardiomyopathic type (Sengers syndrome)<br />(OMIM <a href="http://omim.org/entry/212350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">212350</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acylglycerol kinase</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>MGME1</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11, myopathic type<br />(OMIM <a href="http://omim.org/entry/615084" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615084</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exonuclease in mtDNA replication</td></tr><tr><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SLC25A4</i></td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12B, cardiomyopathic type<br />(OMIM <a href="http://omim.org/entry/615418" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615418</a>)</td><td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adenine nucleotide, translocator, dNTP pools</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">dNTP = deoxyribonucleoside triphosphate</p></div></dd><dt>1. </dt><dd><div id="alpers.TF.3.1"><p class="no_margin">Within each phenotypic category, mtDNA depletion syndromes are ordered by relative prevalence.</p></div></dd><dt>2. </dt><dd><div id="alpers.TF.3.2"><p class="no_margin">See hyperlinked <i>GeneReview</i> or OMIM <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> entry for more information. Additional information on selected disorders appears following the table.</p></div></dd></dl></div></div></div><p><a href="/books/n/gene/dguok-mtddepl/"><b>Deoxyguanosine kinase deficiency</b></a>
<b>(DGUOK deficiency).</b> The two forms of DGUOK deficiency are a hepatocerebral mtDNA depletion syndrome (multisystem disease in neonates) and <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hepatic disease later in infancy or childhood. The majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have the multisystem illness with hepatic disease (jaundice, cholestasis, and elevated transaminases) and neurologic manifestations (hypotonia, nystagmus, and psychomotor retardation) evident within weeks of birth. In contrast to AHS caused by <i>POLG</i> pathogenic variants, DGUOK deficiency is not characterized by seizures or brain imaging abnormalities [<a class="bk_pop" href="#alpers.REF.dimmock.2008.330">Dimmock et al 2008</a>]. Those with isolated liver disease may also have renal involvement and some later develop mild hypotonia. Progressive hepatic disease is the most common cause of death in both forms. Reduced mtDNA copy number in liver or muscle can be used to confirm mtDNA depletion. Molecular genetic testing of <i>DGUOK</i> is necessary to establish the specific diagnosis of DGUOK deficiency [<a class="bk_pop" href="#alpers.REF.mandel.2001.337">Mandel et al 2001</a>].</p><p><a href="/books/n/gene/mpv17-mtdep/"><b><i>MPV17</i>-related hepatocerebral mtDNA depletion syndrome</b></a>
<b>(Navajo neurohepatopathy)</b> is characterized by liver failure, severe sensory neuropathy, corneal anesthesia and scarring, cerebral leukoencephalopathy, failure to thrive, and metabolic acidosis. Homozygosity for the <i>MPV17</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a href="/protein/NP_002428.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002428.1</a>:p.Arg50Gln (<a href="/nuccore/NM_002437.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002437.4</a>:c.149G&#x0003e;A) is associated with Navajo neurohepatopathy, a mtDNA depletion syndrome displaying hepatic failure early in life, prevalent in the Navajo tribes in the southwestern United States.</p><p><a href="/books/n/gene/sucla2-def/"><b><i>SUCLA2</i></b>-<b>related mtDNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria</b></a> is characterized by severe hypotonia in early infancy (birth to 5 months), severe muscular atrophy with failure to achieve independent ambulation, progressive scoliosis or kyphosis, dystonia and/or hyperkinesias (i.e., athetoid or choreiform movements), epilepsy (infantile spasms or generalized convulsions with onset from birth to 3 years) in a few children, postnatal growth retardation, and severe sensorineural hearing impairment. The outcome is poor with early lethality. Metabolic findings usually include urinary excretion of methylmalonic acid (MMA), elevated plasma methylmalonic acid concentration, and elevated plasma lactate concentration. Plasma carnitine ester profiling shows increased C3-carnitine and C4-dicarboxylic-carnitine. Urinary excretion of C4-dicarboxylic carnitine is usually approximately 20 times normal. CT/MRI may show central and cortical atrophy, bilateral basal ganglia involvement (mainly the putamen and caudate nuclei), and delayed myelination.</p><p><a href="/books/n/gene/fbxl4-mtddepl/"><b><i>FBXL4</i>-related encephalomyopathic mtDNA depletion syndrome</b></a> is a multisystem disorder characterized primarily by <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> or early-onset lactic acidosis and growth failure, feeding difficulty, hypotonia, and global developmental delay. Other neurologic manifestations can include seizures, movement disorders, ataxia, autonomic dysfunction, and stroke-like episodes. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals alive at the time they were reported (median age: 3.5 years) demonstrated significant global developmental delay. Other findings can involve the heart (hypertrophic cardiomyopathy, congenital heart malformations, arrhythmias), liver (mildly elevated transaminases), eyes (cataract, strabismus, nystagmus, optic atrophy), hearing (sensorineural hearing loss), and bone marrow (neutropenia, lymphopenia). Survival varies; the median age of reported deaths was two years (range 2 days - 75 months), although surviving individuals as old as 36 years have been reported. To date <i>FBXL4</i>-related mtDNA depletion syndrome has been reported in 50 individuals.</p><p><a href="/books/n/gene/suclg1-mtddepl/"><b><i>SUCLG1-</i>related mtDNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria</b></a> is characterized in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> newborns by hypotonia, muscle atrophy, feeding difficulties, and lactic acidosis. Affected infants commonly manifest developmental delay / cognitive impairment, growth retardation / failure to thrive, hepatopathy, sensorineural hearing impairment, dystonia, and hypertonia. Notable findings in some affected individuals include hypertrophic cardiomyopathy, epilepsy, myoclonus, microcephaly, sleep disturbance, rhabdomyolysis, contractures, hypothermia, and/or hypoglycemia. Life span is shortened, with median survival of 20 months. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be indistinguishable from <i>SUCLA2</i>-related mtDNA depletion syndrome, encephalomyopathic form, with mild methylmalonic aciduria. Affected individuals have urinary excretion of MMA, combined respiratory chain enzyme deficiency, and mtDNA depletion.</p><p><a href="/books/n/gene/rrm2b-mtddepl/"><b><i>RRM2B-</i>related mitochondrial disease</b></a><b><i>.</i></b> Mutation of <i>RRM2B</i> has been associated with severe muscle mtDNA depletion in several families. This disorder manifests as severe encephalopathy, myopathy with persistent lactic acidosis, hypotonia, renal tubular defects, seizures, and diarrhea. Death has been reported to occur by age four months, but <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have demonstrated longer survival [B Cohen, personal communication].</p><p><a href="/books/n/gene/mngie/"><b>Mitochondrial neurogastrointestinal encephalopathy</b></a>
<b>(MNGIE)</b> is characterized by progressive gastrointestinal dysmotility (manifesting as early satiety, nausea, dysphagia, gastroesophageal reflux, postprandial emesis, episodic abdominal pain and/or distention, and diarrhea); cachexia; ptosis/ophthalmoplegia or ophthalmoparesis; leukoencephalopathy; and demyelinating peripheral neuropathy (manifesting as paresthesias [tingling, numbness, and pain] and symmetric and distal weakness more prominently affecting the lower extremities). The order in which manifestations appear is unpredictable. Onset is usually between the first and fifth decades; in about 60% of individuals, symptoms begin before age 20 years. The diagnosis of MNGIE disease can be established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by detection of one of the following: (1) <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TYMP</i>; (2) markedly reduced levels of thymidine phosphorylase enzyme activity; or (3) elevated plasma concentrations of thymidine and deoxyuridine.</p><p><a href="/books/n/gene/tk2-mtddepl/"><b><i>TK2-</i>related mtDNA depletion syndrome</b></a><b>.</b> Mitochondrial myopathy with mtDNA depletion is caused by pathogenic variants in <i>TK2</i>.</p><p><b><i>MGME1-</i>related mtDNA depletion syndrome 11</b> (OMIM <a href="http://omim.org/entry/615084" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615084</a>) is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>MGME1.</i> Individuals present between ages ten and 36 years with ptosis, followed by mild PEO, diffuse skeletal muscle wasting and myopathy, profound emaciation, and respiratory failure. Intellectual disability was found in only one family of three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><b><i>SLC25A4-</i>related mtDNA depletion syndrome 12B,</b>
<b>cardiomyopathic type</b> (OMIM <a href="http://omim.org/entry/615418" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615418</a>) is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC25A4</i>. Affected individuals may present with the SANDO (ANS) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div><div id="alpers.Other_Disorders_to_Consider"><h3>Other Disorders to Consider</h3><p><b>Leigh syndrome</b> is a progressive neurodegenerative disorder characterized by hypotonia, spasticity, dystonia, muscle weakness, hypo- or hyperreflexia, seizures, movement disorders, cerebellar ataxia, and peripheral neuropathy. In individuals with Leigh syndrome MRI changes most often occur initially in the brain stem and the gliosis "migrates" over time to involve the deep gray masses and cortex, whereas in AHS the initial lesions form in the cerebral cortex (usually the occipital lobes), followed by the cerebellum, basal ganglia, thalamus, and brain stem. (See <a href="/books/n/gene/leigh-nucl-ov/">Nuclear Gene-Encoded Leigh Syndrome Overview</a>, <a href="/books/n/gene/narp/">Mitochondrial DNA-Associated Leigh Syndrome and NARP</a>, and <a href="/books/n/gene/kss/">Mitochondrial DNA Deletion Syndromes</a>.)</p><p><b>Autosomal dominant progressive external ophthalmoplegia</b> (<a href="http://omim.org/phenotypicSeries/PS157640" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM PS157640</a>) is caused by pathogenic variants in <i>DGUOK</i>, <i>DNA2</i>, <i>OPA1</i>, <i>POLG2</i>, <i>RNASEH1</i>, <i>RRM2B</i>, <i>SLC25A4</i>, <i>TK2</i>, or <i>TWNK</i>.</p><p><a href="/books/n/gene/opmd/"><b>Oculopharyngeal muscular dystrophy</b></a> (OPMD) with onset usually after age 45 years may result in progressive ptosis and bulbar dysfunction manifest as swallowing difficulty. This disorder may mimic the clinical manifestations of the <i>POLG</i>-related disorders in which PEO is the predominant feature. OPMD is caused by pathogenic variants in <i>PABPN1</i> and inherited in either an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/amish-mcph/"><b>Amish lethal microcephaly</b></a> is characterized by microcephaly and early death. The occipitofrontal circumference is typically six to 12 SD below the mean; anterior and posterior fontanels are closed at birth and facial features are distorted. The average life span is between five and six months. Diagnosis is based on a tenfold increase in the levels of the urinary organic acid 2-ketoglutarate. <i>SLC25A19</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with Amish lethal microcephaly. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals within the Old Order Amish population are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the same single-<a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a> substitution.</p><p><b>Chronic progressive external ophthalmoplegia (CPEO)</b> in a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case or when there is a maternal family history can be the result of a large-scale single <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of mtDNA that may only be detected in limited tissues (e.g., skeletal muscle). CPEO is sometimes complicated by mild proximal muscle weakness and dysphagia, and can be considered to lie on a spectrum of disease from pure CPEO to the Kearns-Sayre syndrome. Some individuals with CPEO (&#x0003c;20%) have a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/single-nucleotide-variant/">single-nucleotide variant</a> of mtDNA (e.g., m.3243A&#x0003e;G).</p><p><a href="/books/n/gene/kss/"><b>Kearns-Sayre syndrome</b></a>
<b>(KSS),</b> a mtDNA <a class="def" href="/books/n/gene/glossary/def-item/deletion-syndrome/">deletion syndrome</a>, is a multisystem disorder defined by the triad of onset before age 20 years, pigmentary retinopathy, and progressive external ophthalmoplegia (PEO). In addition, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have at least one of the following: cardiac conduction block, cerebrospinal fluid protein concentration greater than 100 mg/dL, or cerebellar ataxia. Onset is usually in childhood. PEO, characterized by ptosis, paralysis of the extraocular muscles (ophthalmoplegia), and variably severe proximal limb weakness, is relatively benign. Mitochondrial DNA deletion syndromes are caused by deletion of mtDNA and, when inherited, are transmitted by maternal inheritance. Most individuals with KSS have a common deletion of 4,977 nucleotides involving 12 mitochondrial genes.</p><p><b><i>BCS1L-</i>related disorders<i>.</i></b> Pathogenic variants in <i>BCS1L</i> are associated with GRACILE (<i>g</i>rowth <i>r</i>estriction, <i>a</i>minoaciduria, <i>c</i>holestasis, <i>i</i>ron overload, <i>l</i>actic acidosis, and <i>e</i>arly death) syndrome (OMIM <a href="http://omim.org/entry/603358" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603358</a>), Bj&#x000f8;rnstad syndrome (<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> profound hearing loss and <i>pili torti</i>) (OMIM <a href="http://omim.org/entry/262000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">262000</a>), and an overlapping GRACILE syndrome-Bj&#x000f8;rnstad syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Children with the pure form of Bj&#x000f8;rnstad syndrome have normal intellect. The BCS1L protein is an assembly factor for complex III responsible for insertion of the Fe-S core into the complex. Affected children have a biochemical defect in complex III. The clinical scenario of a hepatoencephalopathy may appear similar to AHS at a single point in time, but mtDNA depletion is not part of the pathology described in those with <i>BCS1L</i> pathogenic variants.</p><p><b><i>SCO1-</i>related disorders</b> (OMIM <a href="http://omim.org/entry/603644" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603644</a>). Hepatic failure and severe encephalopathy have also been associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SCO1</i>.</p><p><b>Infantile or late-infantile progressive encephalopathies with primary involvement of cortical gray matter and refractory epilepsy</b></p><ul><li class="half_rhythm"><div><b>Neuronal ceroid-lipofuscinoses</b>
<b>(NCLs)</b> are a group of inherited, neurodegenerative, lysosomal storage disorders characterized by progressive mental and motor deterioration, seizures, and early death. Visual loss is a feature of most forms. Phenotypes included in the NCLs that overlap with AHS are CLN1 disease, classic infantile (previously classic infantile NCL, INCL, Santavuori-Haltia), and CLN2 disease, classic late infantile (previously late-infantile NCL, LINCL, Jansky-Bielschowsky disease). Inheritance of CLN1 disease and CLN2 disease is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div><ul><li class="half_rhythm"><div><b>CLN1 disease.</b> Children with CLN1 disease are normal at birth; symptoms usually present acutely between ages six and 24 months. Initial signs include delayed development, myoclonic jerks and/or seizures, deceleration of head growth, and specific EEG changes. Affected infants develop retinal blindness and seizures by age two years, followed by progressive mental deterioration. Pathogenic variants in <i>PPT1</i> can be causative.</div></li><li class="half_rhythm"><div><b>CLN2 disease.</b> The first symptoms of CLN2 disease typically appear between age two and four years, usually starting with epilepsy, followed by regression of developmental milestones, dementia, ataxia, and extrapyramidal and pyramidal signs. Visual impairment typically appears between ages four and six years and rapidly progresses to blindness. Life expectancy ranges from age six years to greater than age 40 years. Pathogenic variants in <i>PPT1</i>, <i>TPP1</i>, <i>CLN5</i>, <i>CLN6</i>, and <i>CLN8</i> can be causative.</div></li></ul></li><li class="half_rhythm"><div><a href="/books/n/gene/merrf/"><b>MERRF</b></a> (<i>m</i>yoclonic <i>e</i>pilepsy with <i>r</i>agged <i>r</i>ed <i>f</i>ibers) is a multisystem disorder characterized by myoclonus (often the first symptom) followed by generalized epilepsy, ataxia, weakness, and dementia. Onset is usually in childhood, following normal early development. Common findings are hearing loss, short stature, optic atrophy, and cardiomyopathy with Wolff-Parkinson-White syndrome. Occasionally pigmentary retinopathy and lipomatosis are observed. MERRF is transmitted by maternal inheritance.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/melas/"><b>MELAS</b></a> (<i>m</i>itochondrial <i>e</i>ncephalomyopathy, <i>l</i>actic <i>a</i>cidosis, and <i>s</i>trokelike episodes) is a multisystem disorder with onset typically occurring in childhood. Early psychomotor development is usually normal. Onset of symptoms is often between ages two and ten years. The most common initial symptoms are generalized tonic-clonic seizures, recurrent headaches, anorexia, and recurrent vomiting. Seizures are often associated with stroke-like episodes of transient hemiparesis or cortical blindness. The cumulative residual effects of the stroke-like episodes gradually impair motor abilities, vision, and mentation, often by adolescence or young adulthood. Sensorineural hearing loss is common. MELAS is transmitted by maternal inheritance.</div></li><li class="half_rhythm"><div><b>Storage diseases</b> during infancy and early childhood, such as atypical <a href="/books/n/gene/tay-sachs/">hexosaminidase A deficiency</a>, Sandhoff disease (OMIM <a href="http://omim.org/entry/268800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">268800</a>), infantile sialidosis (OMIM <a href="http://omim.org/entry/256550" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">256550</a>), and galactosialidosis (OMIM <a href="http://omim.org/entry/256540" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">256540</a>), can be diagnosed by testing for lysosomal enzyme activity in the appropriate tissue.</div></li><li class="half_rhythm"><div><b>Other rare neonatal-onset causes</b> of a progressive encephalopathy with refractory seizures include <a href="/books/n/gene/pds/">pyridoxine-dependent epilepsy</a>, cerebral folate deficiency (OMIM <a href="http://omim.org/entry/613068" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613068</a>), <a href="/books/n/gene/nkh/">glycine encephalopathy</a> (also known as nonketotic hyperglycinemia), <a href="/books/n/gene/biotin/">biotinidase deficiency</a>, and disorders of biogenic amine metabolism, such as folate-responsive seizures (see <a href="/books/n/gene/folate-mal/">Hereditary Folate Malabsorption</a>). Pyridoxine-dependent seizures and biotinidase deficiency are treatable and on occasion reversible [<a class="bk_pop" href="#alpers.REF.wolf.2005.441">Wolf 2005</a>, <a class="bk_pop" href="#alpers.REF.gallagher.2009.550">Gallagher et al 2009</a>].</div></li><li class="half_rhythm"><div><b>Sulfite oxidase deficiency</b> (OMIM <a href="http://omim.org/entry/272300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">272300</a>) and <b>Menkes disease</b> (see <a href="/books/n/gene/menkes/"><i>ATP7A</i>-Related Copper Transport Disorders</a>) usually present earlier in infancy. Sulfite oxidase deficiency can be screened for by use of a commercially available sulfite oxidase urine dipstick test and Menkes disease by detection of low serum concentrations of copper and ceruloplasmin. Menkes disease is caused by pathogenic variants in <i>ATP7A</i> and in inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</div></li></ul><p><b>Slow virus diseases</b> (subacute sclerosing panencephalitis) are extremely rare at this age.</p><p>Within the differential diagnosis are also <b>epileptic syndromes</b> that appear to be progressive at the onset but that usually plateau into developmental arrest/delay.</p><p>The <b>channelopathies</b> are with a group of severe infantile epileptic disorders caused by pathogenic variants in <i>CACNA1A</i>, <i>CACNB4</i>, <i>SCN1A</i>, <i>SCN2A</i>, or <i>SCN9A</i> which encode for sodium and calcium channels. See <a href="/books/n/gene/gefs/"><i>SCN1A</i>-Related Seizure Disorders</a>.</p><p>Both <b>myoclonic epilepsy</b> (OMIM <a href="http://omim.org/phenotypicSeries/PS254800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS254800</a>) and the <b>Lennox-Gastaut syndrome</b> can cause dementia or pseudodementia as a result of unrelenting seizures and anticonvulsant side effects.</p></div></div><div id="alpers.Management"><h2 id="_alpers_Management_">Management</h2><div id="alpers.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with a <i>POLG</i>-related disorder, evaluation should always include measures of functional neurologic status.</p><p>In order to determine the baseline function for a given <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, it is reasonable to conduct the following evaluations as appropriate for the phenotypic presentation if they have not already been completed:</p><ul><li class="half_rhythm"><div class="half_rhythm">Electroencephalogram (EEG) and video EEG monitoring</div></li><li class="half_rhythm"><div class="half_rhythm">Formal developmental assessment to provide a baseline of function as well as offer insights into the need for occupational, physical, and/or speech therapy</div></li><li class="half_rhythm"><div class="half_rhythm">Brain MRI. On occasion the first neuroimaging study may be normal, but with certain phenotypes, such as AHS, changes may be seen in a relatively short amount of time.</div></li><li class="half_rhythm"><div class="half_rhythm">Echocardiogram and electrocardiogram</div></li><li class="half_rhythm"><div class="half_rhythm">Ophthalmology evaluation with vision assessment</div></li><li class="half_rhythm"><div class="half_rhythm">Audiology evaluation</div></li><li class="half_rhythm"><div class="half_rhythm">Swallowing study if bulbar signs are present</div></li><li class="half_rhythm"><div class="half_rhythm">Nutritional assessment</div></li><li class="half_rhythm"><div class="half_rhythm">Baseline pulmonary function testing</div></li><li class="half_rhythm"><div class="half_rhythm">Sleep polysomnogram specifically for the purpose of evaluating for central or obstructive apnea or hypopnea that result in either pCO<sub>2</sub> elevation or O<sub>2</sub> desaturation</div></li><li class="half_rhythm"><div class="half_rhythm">Liver function tests including fasting serum glucose concentration, ALT, and AST; serum concentrations of ammonia, glutamine and tyrosine (found in an amino acid panel), bilirubin, albumin, and cholesterol; and the coagulation factors (prothrombin time or INR)</div><div class="half_rhythm">Note: AST elevation, and to a lesser extent ALT elevation, may be due to muscle disease; simultaneously obtaining a serum CK level differentiates between liver and muscle involvement, although both liver and muscle disease can be seen in individuals with <i>POLG</i>-related disorders.</div></li><li class="half_rhythm"><div class="half_rhythm">Consideration of liver ultrasound examination to evaluate for presence of fibrosis</div></li><li class="half_rhythm"><div class="half_rhythm">Consultation with a biochemical geneticist and/or genetic counselor</div></li></ul></div><div id="alpers.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment is limited to symptom management and supportive care.</p><div id="alpers.AlpersHuttenlocher_Syndrome"><h4>Alpers-Huttenlocher Syndrome</h4><p><b>Family education</b> is critical. It is important to address the quality of life / intensity of treatment issues frequently and when major changes occur in disease status. Once the family has started the process of accepting the diagnosis, it is important to involve the family with options for supportive care that can be offered as the illness progresses. These will include (but are not limited to) the use of a gastrostomy feeding tube and the different levels of artificial ventilation that could include less invasive treatments such as CPAP or BiPAP, assisted nasal ventilation, and/or intubation, and the use of a tracheostomy and ventilator. Involvement of palliative care services can assist the care team in these discussions, as well as in practical aspects of implementation. Although rehabilitative services are a necessary part of the treatment and care plan for these children, and rehabilitation units are often where parents of children with new gastrostomy tubes and ventilator support learn to care for their children, the global perspective of care should be palliative even if death is not imminent.</p><p><b>Supportive therapies.</b> Occupational, physical, and/or speech therapy is indicated to maintain neurologic function for as long as possible and to insure comfort when deterioration begins.</p><p><b>Gastrointestinal.</b> A consult with a gastroenterologist regarding feeding or nutritional issues or evidence of liver involvement may be appropriate. Surgical placement of a gastric feeding tube when appropriate can maintain nutritional status and/or prevent aspiration of oral feeding.</p><p><b>Hepatic.</b> Standard treatment for liver failure may include small frequent meals or continuous feeding to compensate for defective gluconeogenesis, reduction in dietary protein to a minimum, use of non-absorbable sugars to create an osmotic diarrhea, and use of conjugating agents to treat hyperammonemia.</p><p>Because levocarnitine may have some benefit in the setting of liver failure and because of its low toxicity, some recommend its use from the time of diagnosis.</p><p><b>Respiratory.</b> Tracheostomy placement and artificial ventilation may be performed as appropriate.</p><p>Assessment of nocturnal ventilatory function can be performed for evidence of central and/or obstructive apnea using polysomnography with measurement of pCO<sub>2</sub> and monitoring by pulse oximetry. Treatment with CPAP or BiPAP as indicated is appropriate.</p><p><b>Seizures.</b> Seizure control is a goal of treatment; however, refractory epilepsy, especially epilepsia partialis continua (EPC), may be impossible to control with any treatment. In individuals with EPC, the use of high-dose anticonvulsants may control the clinical seizures, but the associated obtundation with subsequent risk of aspiration and ventilatory failure may outweigh the benefit.</p><p>Although anticonvulsant monotherapy is preferred, treatment with more than one medication often becomes necessary as the child's seizures worsen and as multiple types of seizures occur. If high-dose anticonvulsant therapy is not effective in improving the quality of life by reducing the seizure burden, reducing the number and/or dose of medications may improve quality of life by reducing medication side effects.</p><p>There is no evidence that newer anticonvulsants such as felbamate, lamotrigine, topiramate, oxcarbazepine, or levetiracetam offer a better therapeutic benefit than older medications (phenobarbital, phenytoin, carbamazepine, primidone); however, the newer medications tend to be less sedating, may require less processing by the liver, and have fewer drug-drug interactions. Intravenous magnesium, used most often to treat seizures in eclampsia, has shown efficacy in one report where <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with status epilepicus were refractory to other typical anticonvulsants [<a class="bk_pop" href="#alpers.REF.visser.2011.218">Visser et al 2011</a>].</p><p>One unpublished pathway for management of seizures is to begin with lamotrigine monotherapy, and when this is no longer effective for adequate control of seizures, to add lacosamide. Adding clobazam may also help when these medications are no longer effective [RP Saneto, personal communication]. With the exception of valproate (see Note), other standard anticonvulsants are reasonable to use, although medications that are heavily metabolized by the liver, such as phenytoins or the barbiturates, should be reserved until other medications fail.</p><p>Note: Valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) should be avoided (see <a href="#alpers.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>). Because other anticonvulsants have also been implicated in accelerating liver deterioration, it is reasonable to monitor liver enzymes every two to four weeks after introducing any new anticonvulsant [<a class="bk_pop" href="#alpers.REF.bicknese.1992.767">Bicknese et al 1992</a>].</p><p><b>Movement disorder.</b> In addition to electroencephalographic seizures, myoclonus and other non-epileptic movement disorders occur as part of AHS and can be as disabling as seizures. These movements should not be confused with seizures, and video EEG is often the only way to differentiate a seizure from a non-epileptic movement disorder. The use of benzodiazepines often reduces the severity of these abnormal movements and also assists in seizure management and reduction of spasticity.</p><p>Chorea and athetosis [<a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al 2005</a>] may cause pain, and treatment with muscle relaxants and pain medications, including narcotics, would be advised. Some movement disorders can be treated with dopaminergic medication such as levodopa-carbidopa or tetrabenazine; a trial of either of these medications can be considered.</p><p>In most individuals, some seizures and/or non-epileptic movements cannot be suppressed with medication, and a balance between the adverse effects of the medication(s) and the disability created by the seizures or movements must be accepted by both the family and physician. Often a modest reduction in seizure control is offset by an improved level of alertness, although the benefit may not be lasting.</p></div><div id="alpers.Other_Phenotypes"><h4>Other Phenotypes</h4><p>Management is supportive and involves conventional approaches such as physiotherapy, speech therapy, and seizure management.</p><p>Gastrostomy may be required to provide adequate nutrition.</p><p>Surgery for ptosis may provide symptomatic relief for some.</p></div></div><div id="alpers.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p>For individuals with any of the <i>POLG</i>-related phenotypes, dose reduction in medications metabolized by hepatic enzymes may be necessary to avoid toxicity.</p><p>Reports suggest that CSF folate may be deficient in disorders that lead to mtDNA depletion [<a class="bk_pop" href="#alpers.REF.hasselmann.2010.58">Hasselmann et al 2010</a>]. Therefore, testing for CSF folate deficiency and offering treatment to those with deficiency is one option; the other option is empiric therapy with folinic acid (calcium leucovorin).</p></div><div id="alpers.Surveillance"><h3>Surveillance</h3><p>Individuals with <i>POLG</i>-related disorders require frequent examination and interval evaluation by a team comprising the following:</p><ul><li class="half_rhythm"><div>Primary care provider</div></li><li class="half_rhythm"><div>Neurologist</div></li><li class="half_rhythm"><div>Biochemical geneticist</div></li><li class="half_rhythm"><div>Hepatologist or gastroenterologist</div></li><li class="half_rhythm"><div>Physiatrist</div></li><li class="half_rhythm"><div>Psychiatrist</div></li><li class="half_rhythm"><div>Neuropsychologist and/or psychologist</div></li><li class="half_rhythm"><div>Ophthalmologist</div></li><li class="half_rhythm"><div>Pulmonologist</div></li></ul><div id="alpers.Laboratory_Tests"><h4>Laboratory Tests</h4><p>No standard-of-care guidelines regarding the recommended frequency of the following tests are available. Testing should be guided by clinical features and the proposed schedule should be modified if the clinical course is stable. For those with the most severe phenotypes, the following could be considered.</p><p>Every three months:</p><ul><li class="half_rhythm"><div>Complete blood count</div></li><li class="half_rhythm"><div>Electrolytes</div></li><li class="half_rhythm"><div>Liver enzymes (AST, ALT, GGT)</div></li><li class="half_rhythm"><div>CK</div></li><li class="half_rhythm"><div>Liver function tests including:</div><ul><li class="half_rhythm"><div>Preprandial serum glucose concentration</div></li><li class="half_rhythm"><div>Serum concentration of ammonia, albumin, bilirubin (free and conjugated), and cholesterol</div></li><li class="half_rhythm"><div>PT or INR as a measure of coagulation factors</div></li></ul></li></ul><p>Annually:</p><ul><li class="half_rhythm"><div>Urine analysis</div></li><li class="half_rhythm"><div>Serum concentration of lactic acid</div></li></ul><p>Biannually:</p><ul><li class="half_rhythm"><div>Plasma amino acids</div></li><li class="half_rhythm"><div>Urine organic acids</div></li><li class="half_rhythm"><div>Plasma concentration of free and total carnitine (unless treated with levocarnitine, in which case measure annually)</div></li></ul><p>Note: After introducing any new anticonvulsant it is reasonable to monitor liver enzymes every two to four weeks.</p></div><div id="alpers.Imaging_and_Diagnostic_Procedures"><h4>Imaging and Diagnostic Procedures</h4><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Liver ultrasound examination annually</div></li><li class="half_rhythm"><div>EEG and video EEG monitoring (e.g., for suspicion of subclinical status epilepticus, presence of epilepsia partialis continua, need to determine if events are seizures or non-epileptic movements)</div></li><li class="half_rhythm"><div>Audiogram and brain stem auditory evoked responses as clinically indicated</div></li><li class="half_rhythm"><div>Barium swallow study as clinically indicated</div></li><li class="half_rhythm"><div>Polysomnogram with CPAP titration as part of an evaluation of subacute mental status changes or every two to three years</div></li></ul></div></div><div id="alpers.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) should be avoided because of the risk of precipitating and/or accelerating liver disease [<a class="bk_pop" href="#alpers.REF.saneto.2010.140">Saneto et al 2010</a>].</p><p>As with some other mitochondrial diseases, physical stressors such as infection, fever, dehydration, and anorexia can result in a sudden deterioration and should be avoided if possible.</p></div><div id="alpers.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#alpers.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="alpers.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="alpers.Other"><h3>Other</h3><p>Liver transplantation is not advised in children with AHS because transplanting the liver does not alter the rapid progression of the brain disease [<a class="bk_pop" href="#alpers.REF.kelly.2000.170">Kelly 2000</a>].</p><p>However, liver transplantation in adults who have an acceptable quality of life may be of benefit:</p><ul><li class="half_rhythm"><div>In one report, one of two individuals undergoing liver transplantation survived [<a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>].</div></li><li class="half_rhythm"><div>In another report, a woman underwent liver transplantation at age 19 years, eight years after experiencing fulminant hepatic failure following onset of valproate therapy. Molecular genetic testing seven years after her liver transplantation confirmed the diagnosis of a <i>POLG</i>-related disorder; her <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> fit best with SANDO [<a class="bk_pop" href="#alpers.REF.wong.2008.e150">Wong et al 2008</a>]. As of late 2017 (20 years after liver transplantation), she was alive and living semi-independently, albeit with severe PEO, myopathy, and progressive CNS dysfunction, specifically failing memory with increasing ataxia, dysarthria, chorea, and hemiballismus. Although seizures were a presenting symptom, they are currently controlled.</div></li></ul><p>The use of other treatments for refractory epilepsy, such as corticotropin or prednisone, ketogenic diet, and intravenous IgG, are unproven in the treatment of AHS. The following, however, may be considered:</p><ul><li class="half_rhythm"><div>Vitamin and cofactor therapy with the intent to fortify mitochondrial function may be offered. There have not been formal studies of the use of these vitamins and cofactors in AHS or other <i>POLG</i>-related disorders [<a class="bk_pop" href="#alpers.REF.parikh.2009.414">Parikh et al 2009</a>, <a class="bk_pop" href="#alpers.REF.camp.2016.187">Camp et al 2016</a>].</div></li><li class="half_rhythm"><div>The use of folinic acid should be strongly considered (see <a href="#alpers.Prevention_of_Secondary_Complicat">Prevention of Secondary Complications</a>).</div></li><li class="half_rhythm"><div>The use of levo-arginine has been reported helpful in reducing the frequency and severity of the strokes associated with <a href="/books/n/gene/melas/">MELAS</a>, and can be considered for use in persons with <i>POLG</i>-related disorders, especially if deficiency in the plasma or CSF arginine concentration is confirmed [<a class="bk_pop" href="#alpers.REF.elhattab.2017.1">El-Hattab et al 2017</a>].</div></li><li class="half_rhythm"><div>Levocarnitine, creatine monohydrate, coenzyme Q<sub>10</sub>, B vitamins, and antioxidants such as alpha lipoic acid, vitamin E, and vitamin C have been used as mitochondrial supplements. Use of all in <i>POLG</i>-related disorders is reasonable based on limited published evidence and their general lack of toxicity [<a class="bk_pop" href="#alpers.REF.gold.2001.309">Gold &#x00026; Cohen 2001</a>, <a class="bk_pop" href="#alpers.REF.rodriguez.2007.235">Rodriguez et al 2007</a>, <a class="bk_pop" href="#alpers.REF.horvath.2008.558">Horvath et al 2008</a>, <a class="bk_pop" href="#alpers.REF.parikh.2013.681">Parikh et al 2013</a>].</div></li></ul></div></div><div id="alpers.Genetic_Counseling"><h2 id="_alpers_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="alpers.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>The following <i>POLG</i>-related disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner:</p><ul><li class="half_rhythm"><div>Alpers-Huttenlocher syndrome (AHS)</div></li><li class="half_rhythm"><div>Childhood myocerebrohepatopathy spectrum (MCHS)</div></li><li class="half_rhythm"><div>Myoclonic epilepsy myopathy sensory ataxia (MEMSA); previously referred to as spinocerebellar ataxia with epilepsy (SCAE)</div></li><li class="half_rhythm"><div>Ataxia neuropathy spectrum (ANS); includes disorders previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO)</div></li><li class="half_rhythm"><div>Autosomal recessive progressive external ophthalmoplegia (arPEO)</div></li></ul><p>Autosomal dominant progressive external ophthalmoplegia (CPEO+) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div><div id="alpers.Autosomal_Recessive_Inheritance"><h3>Autosomal Recessive Inheritance</h3><div id="alpers.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>In general, the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>). In two families reported to date, only one parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> was <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (i.e., the probands were <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for one inherited and one <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant) [<a class="bk_pop" href="#alpers.REF.chan.2009.340">Chan et al 2009</a>, <a class="bk_pop" href="#alpers.REF.lutz.2009.126">Lutz et al 2009</a>].</div></li><li class="half_rhythm"><div>Heterozygotes are generally believed to be asymptomatic. However, some individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are reported to have partial manifestations of <i>POLG</i>-related disorders; the manifestation cannot be predicted [<a class="bk_pop" href="#alpers.REF.rantam_ki.2007.532">Rantam&#x000e4;ki et al 2007</a>]. Because knowledge of these disorders is changing quickly individuals who are heterozygous should be reevaluated by history and physical examination every few years for symptoms and signs of <i>POLG</i>-related disorders.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, the sibs of an individual with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <i>POLG</i>-related disorder have a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>. Affected sibs may present differently in terms of age of onset and severity.</div></li><li class="half_rhythm"><div>Heterozygotes are generally believed to be asymptomatic. However, some individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are reported to have manifestations of <i>POLG</i>-related disorders. Because knowledge of these disorders is changing quickly individuals who are heterozygous should be reevaluated by history and physical examination every few years for symptoms and signs of <i>POLG</i>-related disorders.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Individuals with some <i>POLG</i>-related disorders (e.g., Alpers-Huttenlocher syndrome) do not reproduce.</div></li><li class="half_rhythm"><div>The offspring of individuals with less severe manifestations of a <i>POLG</i>-related disorder will be obligate heterozygotes for a <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="alpers.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the <i>POLG</i> pathogenic variants in the family.</p><p>Individuals from populations with a high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for <i>POLG</i> pathogenic variants and/or a high rate of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> should be offered <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>.</p></div></div><div id="alpers.Autosomal_Dominant_Inheritance__R"><h3>Autosomal Dominant Inheritance &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>POLG</i>-related disorder have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, although age of onset and severity of presentation can vary greatly from generation to generation.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>POLG</i>-related disorder may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> pathogenic variant is thought to be low (&#x0003c;1%); however, because <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) have not been evaluated sufficiently to determine whether the pathogenic variant was <i>de novo</i>, the proportion of cases caused by a <i>de novo</i> variant is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include performing a complete history and physical examination, focusing on the most common symptoms and/or clinical features of <i>POLG</i>-related disease (ophthalmoplegia, weakness, ataxia, and neuropathy). Because migraine, depression, gastrointestinal problems, and seizures are so common in the general population, their presence as <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> findings is not likely to be relevant. If there is an ophthalmoplegia, or a constellation of features suggestive of <i>POLG</i>-related disease, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be performed to confirm the diagnosis.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent.</div></li><li class="half_rhythm"><div>Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of a milder phenotypic presentation, failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the pathogenic variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%. Although in general the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the illness may be similar in families, affected sibs may present differently in terms of age of onset and severity. For example, in a family in which affected sibs were compound heterozygotes (<i>POLG</i> pathogenic variants <a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.Gly848Ser</a> and <a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.Trp748Ser</a>), one sib presented with developmental delays and status epilepticus at age three, while the other sib presented with ataxia and myoclonus in early adolescence [<a class="bk_pop" href="#alpers.REF.tang.2011.669">Tang et al 2011</a>].</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk (for the disorder) because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <i>POLG</i>-related disorder has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="alpers.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>At-risk family members</b></p><ul><li class="half_rhythm"><div>Sibs who are close in age to or younger than the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may still be at risk and in need of diagnostic evaluation.</div></li><li class="half_rhythm"><div>Older unaffected sibs (as well as other family members) may have only a single <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, but need to be informed that:</div><ul><li class="half_rhythm"><div>Some heterozygotes have had symptoms at a later age &#x02013; possibly related to their genetic status; and</div></li><li class="half_rhythm"><div>Heterozygotes (i.e., those with a single pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) are at increased risk of having a child with the disorder, particularly if their reproductive partner is of an ethnic group with high <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency.</div></li></ul></li></ul><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="alpers.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for a <i>POLG</i>-related disorder are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="alpers.Resources"><h2 id="_alpers_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>Children's Liver Disease Foundation (CLDF)</b></div><div>36 Great Charles Street</div><div> Birmingham B3 3JY</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 121 212 3839</div><div><b>Fax:</b> +44 (0) 121 212 4300</div><div><b>Email:</b> info@childliverdisease.org</div><div><a href="http://www.childliverdisease.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.childliverdisease.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li><li class="half_rhythm"><div><b>Foundation for Mitochondrial Medicine</b></div><div>1266 West Paces Ferry Road</div><div>Suite 301</div><div>Atlanta GA 30327</div><div><b>Phone:</b> 888-448-1495</div><div><b>Email:</b> info@mitochondrialdiseases.org</div><div><a href="http://mitochondrialdiseases.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mitochondrialdiseases.org</a></div></li><li class="half_rhythm"><div><b>MitoAction</b></div><div>P.O. Box 51474</div><div>Boston MA 02205</div><div><b>Phone:</b> 888-648-6228</div><div><b>Email:</b> support@mitoaction.org</div><div><a href="http://www.mitoaction.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mitoaction.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>United Mitochondrial Disease Foundation (UMDF)</b></div><div>8085 Saltsburg Road</div><div>Suite 201</div><div>Pittsburg PA 15239</div><div><b>Phone:</b> 888-317-8633 (toll-free); 412-793-8077</div><div><b>Fax:</b> 412-793-6477</div><div><b>Email:</b> info@umdf.org</div><div><a href="http://www.umdf.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.umdf.org</a></div></li><li class="half_rhythm"><div><b>RDCRN Patient Contact Registry: North American Mitochondrial Disease Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/namdc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Contact Registry</a></div></li></ul></div><div id="alpers.Molecular_Genetics"><h2 id="_alpers_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="alpers.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>POLG-Related Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_alpers.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_alpers.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_alpers.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_alpers.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_alpers.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_alpers.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_alpers.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5428" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>POLG</i></a></td><td headers="hd_b_alpers.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5428" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q26<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_alpers.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P54098" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA polymerase subunit gamma-1</a></td><td headers="hd_b_alpers.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/POLG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">POLG database</a></td><td headers="hd_b_alpers.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=POLG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">POLG</a></td><td headers="hd_b_alpers.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=POLG[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">POLG</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="alpers.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="alpers.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for POLG-Related Disorders (<a href="/omim/157640,174763,203700,258450,607459,613662" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/157640" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">157640</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/174763" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">174763</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POLYMERASE, DNA, GAMMA; POLG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/203700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">203700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/258450" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">258450</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607459" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607459</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS; SANDO</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613662" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613662</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B</td></tr></tbody></table></div></div><div id="alpers.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The mitochondrion comprises almost 1,500 proteins, but only the 13 that comprise small portions of the respiratory chain complexes I, III, IV, and V are encoded by the mitochondrial genome. The terminal portion of energy production occurs in the respiratory chain; disruption of the production and/or assembly of any component leads to a deficiency of ATP and resultant cellular energy failure. Unlike nuclear DNA, mtDNA replicates continuously and independently of cell division. Polymerase (pol) gamma is the only DNA polymerase in humans that replicates and repairs mtDNA.</p><p>Replication of mtDNA requires a heterotrimer of one catalytic subunit of pol gamma and two accessory subunits encoded by <i>POLG2</i> that assist in binding and processing the synthesized DNA. The twinkle protein, encoded by <i>TWNK</i>, functions as the 5'&#x02192;3' DNA helicase.</p><p><b>Gene structure.</b>
<i>POLG</i> comprises 23 exons and is 18,476 bases in length. See <a href="/books/NBK26471/#alpers.molgen.TA">Table A</a> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Benign variants.</b> A number of <i>POLG</i> pathogenic variants have been found to occur <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> with the <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> p.Glu1143Gly, which has a minor <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> of 3%-4%. This variant modulates the pathogenic effect of p.Trp748Ser (see <b>Pathogenic variants</b>).</p><p><b>Pathogenic variants.</b> Pathogenic variants are found throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Almost 200 variants in <i>POLG</i> are reported to cause disease. Of these, more than 75 are associated with AHS.</p><p>Both the p.Ala467Thr and the p.Trp748Ser pathogenic variants are located in the linker region of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><ul><li class="half_rhythm"><div>The most common AHS-causing <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is p.Ala467Thr, located near the exonuclease <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> in the early linker region of pol gamma.</div></li><li class="half_rhythm"><div>The second most common <i>POLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is p.Trp748Ser, which causes AHS, the ataxia-neuropathy spectrum disorders, and PEO. Of note, the p.Glu1143Gly variant modulates the deleterious effect of p.Trp748Ser by partially rescuing activity but decreasing protein stability [<a class="bk_pop" href="#alpers.REF.chan.2006.3473">Chan et al 2006</a>].</div></li><li class="half_rhythm"><div>The mother of a child with a mitochondrial recessive ataxia syndrome/ataxia neuropathy spectrum (MIRAS/ANS) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and compound heterozygosity for p.[Ala467Thr];[Trp748Ser] was herself <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the p.Trp748Ser <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; she developed epilepsy at age 55 years and was found to have an axonal neuropathy, ataxia, mild PEO, and mild parkinsonism [<a class="bk_pop" href="#alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</a>]. The significance of this finding is unknown</div></li></ul><div id="alpers.T.frequency_of_the_most_common_po" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Frequency of the Most Common <i>POLG</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.T.frequency_of_the_most_common_po/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.T.frequency_of_the_most_common_po_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLG</i> Pathogenic Variant</th><th id="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prevalence</th><th id="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th></tr></thead><tbody><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala467Thr</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.6% Belgian</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.van_goethem.2001.211">Van Goethem et al [2001]</a></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0.17%-0.69% European</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.horvath.2006.1674">Horvath et al [2006]</a></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0.69% UK</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.craig.2007.e69">Craig et al [2007]</a></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0% Italian</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.craig.2007.e69">Craig et al [2007]</a></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp748Ser</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.8% Finland</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.hakonen.2005.430">Hakonen et al [2005]</a></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">0% Italian</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#alpers.REF.craig.2007.e69">Craig et al [2007]</a></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly848Ser</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.05%-0.1%</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.[Thr251Ile]+[Pro587Leu]&#x000a0;<sup>1</sup></td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.05%</td><td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alpers.TF.4.1"><p class="no_margin">Indicates a different <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on each of two alleles (see <a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>)</p></div></dd></dl></div></div></div><p>An up-to-date listing of all pathogenic variants is available at <a href="http://tools.niehs.nih.gov/polg/index.cfm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">tools.niehs.nih.gov</a>, managed by William Copeland, PhD.</p><div id="alpers.T.polg_pathogenic_variants_discus" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>POLG</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alpers.T.polg_pathogenic_variants_discus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.695G&#x0003e;A</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg232His</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_3" rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nucleotide/187171275" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002693<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/4505937" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002684<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.752C&#x0003e;T</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr251Ile</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1399G&#x0003e;A</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala467Thr</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1760C&#x0003e;T</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro587Leu</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2243G&#x0003e;C</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp748Ser</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2542G&#x0003e;A</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly848Ser</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2864A&#x0003e;G</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr955Cys</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3488T&#x0003e;G</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met1163Arg</td></tr><tr><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3630dupC<br />(3630insC)</td><td headers="hd_h_alpers.T.polg_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly1211ArgfsTer6<br />(Tyr1210fs1216Ter)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="alpers.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>POLG</i> encodes DNA pol gamma, which has three functional domains:</p><ul><li class="half_rhythm"><div>Exonuclease, responsible for proofreading (first third of protein)</div></li><li class="half_rhythm"><div>Linker region (center of protein)</div></li><li class="half_rhythm"><div>Polymerase, responsible for replication (last third of protein)</div></li></ul><p>Reports suggest that pathogenic variants in each of these three regions of <i>POLG</i> have rather distinct clinical consequences (see <a href="#alpers.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#alpers.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p><p>The clinical features <i>POLG</i>-related disorders most likely result from depletion over time of normal mtDNA with resultant reduced electron transport chain activity. The adPEO-causing pathogenic variants cluster in the active site region of the DNA polymerase.</p><p>The effect of several common pathogenic variants has been studied.</p><ul><li class="half_rhythm"><div>The p.Ala467Thr variant severely reduces DNA polymerase gamma activity (4% of wild type pol gamma activity) by reducing the affinity for dNTPs and lowering catalytic activity [<a class="bk_pop" href="#alpers.REF.chan.2005.31341">Chan et al 2005</a>]. In addition, p.Ala467Thr fails to associate with the POLG2 accessory subunit which is critical for highly processive DNA synthesis (defined as the number of nucleotides incorporated per DNA binding event). The combined defects lead to stalling at the replication fork and depletion of mtDNA over time.</div></li><li class="half_rhythm"><div>The p.Trp748Ser <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in reduced DNA polymerase activity, low processivity, and a severe DNA binding defect, but normal POLG2 interactions [<a class="bk_pop" href="#alpers.REF.chan.2006.3473">Chan et al 2006</a>]. The phenotypic effects of p.Trp748Ser are modulated when <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> with a <a class="def" href="/books/n/gene/glossary/def-item/normal-variant/">normal variant</a> (see <a href="#alpers.Molecular_Pathogenesis">Molecular Pathogenesis</a>, <b>Benign variants</b>). AHS results when the p.[Trp748Ser;p.Glu1143Gly] haplotype occurs in <a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a> configuration with a different pathogenic variant on the other <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (e.g., <a class="figpopup" href="/books/NBK26471/table/alpers.T.polg_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figalpersTpolgpathogenicvariantsdiscus" rid-ob="figobalpersTpolgpathogenicvariantsdiscus">p.Arg232His</a>).</div></li><li class="half_rhythm"><div>The p.Gly848Ser <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in &#x0003c;1% polymerase activity and in a defect in DNA binding function [<a class="bk_pop" href="#alpers.REF.kasiviswanathan.2009.19501">Kasiviswanathan et al 2009</a>].</div></li><li class="half_rhythm"><div>The rare p.Tyr955Cys <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is the most common associated with adPEO, causing severe reduction in DNA polymerase activity (&#x0003c;1% of wild type POLG activity) [<a class="bk_pop" href="#alpers.REF.graziewicz.2004.770">Graziewicz et al 2004</a>]. This pathogenic variant also results in a mutator polymerase, causing a ten- to 100-fold increase in nucleotide mis-<a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> errors, most likely as a consequence of a 45-fold decrease in binding affinity for the incoming nucleoside triphosphates [<a class="bk_pop" href="#alpers.REF.ponamarev.2002.15225">Ponamarev et al 2002</a>].</div></li><li class="half_rhythm"><div>The p.Thr251Ile and p.Pro587Leu variants nearly always occur together on the same <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and in the general population. Individually, these variants cause an approximately 30% reduction in DNA polymerase activity, but together there is a synergistic impairment of polymerase function to levels about 5% of normal [<a class="bk_pop" href="#alpers.REF.debalsi.2017.4198">DeBalsi et al 2017</a>].</div></li></ul></div></div><div id="alpers.References"><h2 id="_alpers_References_">References</h2><div id="alpers.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.antozzi.1995.152">Antozzi C, Franceschetti S, Filippini G, Barbiroli B, Savoiardo M, Fiacchino F, Rimoldi M, Lodi R, Zaniol P, Zeviani M. Epilepsia partialis continua associated with NADH-coenzyme Q reductase deficiency. <span><span class="ref-journal">J Neurol Sci. </span>1995;<span class="ref-vol">129</span>:152–61.</span> [<a href="/pubmed/7608730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7608730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.ashley.2008.2496">Ashley N, O'Rourke A, Smith C, Adams S, Gowda V, Zeviani M, Brown GK, Fratter C, Poulton J. Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations. <span><span class="ref-journal">Hum Mol Genet. </span>2008;<span class="ref-vol">17</span>:2496–506.</span> [<a href="/pmc/articles/PMC2486441/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2486441</span></a>] [<a href="/pubmed/18487244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18487244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.bekheirnia.2012.209">Bekheirnia MR, Zhang W, Eble T, Willis A, Shaibani A, Wong LJC, Scaglia F, Dhar SU. POLG mutation in a patient with cataracts, early-onset distal muscle weakness and atrophy, ovarian dysgenesis and 3-methylglutaconic aciduria. <span><span class="ref-journal">Gene. </span>2012;<span class="ref-vol">499</span>:209–12.</span> [<a href="/pubmed/22405928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22405928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.bicknese.1992.767">Bicknese AR, May W, Hickey WF, Dodson WE. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. <span><span class="ref-journal">Ann Neurol. </span>1992;<span class="ref-vol">32</span>:767–75.</span> [<a href="/pubmed/1471867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1471867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.camp.2016.187">Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, Enns GM, Falk MJ, Goldstein AC, Gopal-Srivastava R, Gorman GS, Hersh SP, Hirano M, Hoffman FA, Karaa A, MacLeod EL, McFarland R, Mohan C, Mulberg AE, Odenkirchen JC, Parikh S, Rutherford PJ, Suggs-Anderson SK, Tang WH, Vockley J, Wolfe LA, Yannicelli S, Yeske PE, Coates PM. Nutritional interventions in primary mitochondrial disorders: developing an evidence base. <span><span class="ref-journal">Mol Genet Metab. </span>2016;<span class="ref-vol">119</span>:187–206.</span> [<a href="/pmc/articles/PMC5083179/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5083179</span></a>] [<a href="/pubmed/27665271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27665271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.chan.2006.3473">Chan SS, Longley MJ, Copeland WC. Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphism in mitochondrial disorders. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:3473–83.</span> [<a href="/pmc/articles/PMC1780027/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1780027</span></a>] [<a href="/pubmed/17088268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17088268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.chan.2005.31341">Chan SS, Longley MJ, Copeland WC. The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit. <span><span class="ref-journal">J Biol Chem. </span>2005;<span class="ref-vol">280</span>:31341–6.</span> [<a href="/pubmed/16024923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16024923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.chan.2009.340">Chan SS, Naviaux RK, Basinger AA, Casas KA, Copeland WC. De novo mutation in POLG leads to haplotype insufficiency and Alpers syndrome. <span><span class="ref-journal">Mitochondrion. </span>2009;<span class="ref-vol">9</span>:340–5.</span> [<a href="/pmc/articles/PMC2748142/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2748142</span></a>] [<a href="/pubmed/19501198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19501198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.cohen.2010.364">Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. <span><span class="ref-journal">Methods. </span>2010;<span class="ref-vol">51</span>:364–73.</span> [<a href="/pubmed/20558295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20558295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.compton.2011.104">Compton AG, Troedson C, Wilson M, Procopis PG, Li FY, Brundage EK, Yamazaki T, Thorburn DR, Wong LJ. Application of oligonucleotide array CGH in the detection of a large intragenic deletion in POLG associated with Alpers syndrome. <span><span class="ref-journal">Mitochondrion. </span>2011;<span class="ref-vol">11</span>:104–7.</span> [<a href="/pubmed/20708716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20708716</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.craig.2007.e69">Craig K, Ferrari G, Tiangyou W, Hudson G, Gellera C, Zeviani M, Chinnery PF. The A467T and W748S POLG substitutions are a rare cause of adult-onset ataxia in Europe. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:E69.</span> [<a href="/pubmed/17438011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17438011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.darin.2001.377">Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">49</span>:377–83.</span> [<a href="/pubmed/11261513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11261513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.davidzon.2006.859">Davidzon G, Greene P, Mancuso M, Klos KJ, Ahlskog JE, Hirano M, DiMauro S. Early-onset familial parkinsonism due to POLG mutations. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">59</span>:859–62.</span> [<a href="/pubmed/16634032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16634032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.debalsi.2017.4198">DeBalsi KL, Longley MJ, Hoff KE, Copeland WC. Synergistic effects of the cis T251I and P587L mitochondrial DNA polymerase gamma disease mutations. <span><span class="ref-journal">J. Biol. Chem. </span>2017;<span class="ref-vol">292</span>:4198–209.</span> [<a href="/pmc/articles/PMC5354484/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5354484</span></a>] [<a href="/pubmed/28154168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28154168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.di_fonzo.2003.498">Di Fonzo A, Bordoni A, Crimi M, Sara G, Del Bo R, Bresolin N, Comi GP. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">22</span>:498–9.</span> [<a href="/pubmed/14635118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14635118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.dimmock.2008.330">Dimmock DP, Zhang Q, Dionisi-Vici C, Carrozzo R, Shieh J, Tang LY, Truong C, Schmitt E, Sifry-Platt M, Lucioli S, Santorelli FM, Ficicioglu CH, Rodriguez M, Wierenga K, Enns GM, Longo N, Lipson MH, Vallance H, Craigen WJ, Scaglia F, Wong LJ. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:330–1.</span> [<a href="/pubmed/18205204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18205204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.elhattab.2017.1">El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treatment of MELAS syndrome. <span><span class="ref-journal">J Inborn Errors Metab Screen. </span>2017;<span class="ref-vol">5</span>:1–5.</span> [<a href="/pmc/articles/PMC5519148/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5519148</span></a>] [<a href="/pubmed/28736735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28736735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.elhattab.2013.186">El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. <span><span class="ref-journal">Neurotherapeutics. </span>2013;<span class="ref-vol">10</span>:186–98.</span> [<a href="/pmc/articles/PMC3625391/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3625391</span></a>] [<a href="/pubmed/23385875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23385875</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.fadic.1997.239">Fadic R, Russell JA, Vedanarayanan VV, Lehar M, Kuncl RW, Johns DR. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:239–45.</span> [<a href="/pubmed/9222196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9222196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.filosto.2003.1279">Filosto M, Mancuso M, Nishigaki Y, Pancrudo J, Harati Y, Gooch C, Mankodi A, Bayne L, Bonilla E, Shanske S, Hirano M, DiMauro S. Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma. <span><span class="ref-journal">Arch Neurol. </span>2003;<span class="ref-vol">60</span>:1279–84.</span> [<a href="/pubmed/12975295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12975295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.gallagher.2009.550">Gallagher RC, Van Hove JL, Scharer G, Hyland K, Plecko B, Waters PJ, Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S, Salomons GS, Rosenberg EH, Struys EA, Jakobs C. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:550–6.</span> [<a href="/pubmed/19142996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19142996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.gold.2001.309">Gold DR, Cohen BH. Treatment of mitochondrial cytopathies. <span><span class="ref-journal">Semin Neurol. </span>2001;<span class="ref-vol">21</span>:309–25.</span> [<a href="/pubmed/11641821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11641821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.graziewicz.2004.770">Graziewicz MA, Longley MJ, Bienstock RJ, Zeviani M, Copeland WC. Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2004;<span class="ref-vol">11</span>:770–6.</span> [<a href="/pubmed/15258572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15258572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.hakonen.2005.430">Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantam&#x000e4;ki M, Goethem GV, Lofgren A, Hackman P, Paetau A, Kaakkola S, Majamaa K, Varilo T, Udd B, Kaariainen H, Bindoff LA, Suomalainen A. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. <span><span class="ref-journal">Am J Hum Genet. </span>2005;<span class="ref-vol">77</span>:430–41.</span> [<a href="/pmc/articles/PMC1226208/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226208</span></a>] [<a href="/pubmed/16080118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16080118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.harrower.2008.133">Harrower T, Stewart JD, Hudson G, Houlden H, Warner G, O'Donovan DG, Findlay L, Taylor RW, De Silva R, Chinnery PF. POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease. <span><span class="ref-journal">Arch Neurol. </span>2008;<span class="ref-vol">65</span>:133–6.</span> [<a href="/pubmed/18195151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18195151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.hasselmann.2010.58">Hasselmann O, Blau N, Ramaekers VT, Quadros EV, Sequeira JM, Weissert M. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">99</span>:58–61.</span> [<a href="/pubmed/19766516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19766516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.hikmat.2016.1188">Hikmat O, Tzoulis C, Knappskog PM, Johansson S, Boman H, Sztromwasser P, Lien E, Brodtkorb E, Ghezzi D, Bindoff LA. ADCK3 mutations with epilepsy, stroke-like episodes and a POLG mimic? <span><span class="ref-journal">Eur J Neurol. </span>2016;<span class="ref-vol">23</span>:1188–94.</span> [<a href="/pubmed/27106809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27106809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.horvath.2008.558">Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to treatment. <span><span class="ref-journal">Neurotherapeutics. </span>2008;<span class="ref-vol">5</span>:558–68.</span> [<a href="/pmc/articles/PMC4514691/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4514691</span></a>] [<a href="/pubmed/19019307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19019307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.horvath.2006.1674">Horvath R, Hudson G, Ferrari G, F&#x000fc;tterer N, Ahola S, Lamantea E, Prokisch H, Lochm&#x000fc;ller H, McFarland R, Ramesh V, Klopstock T, Freisinger P, Salvi F, Mayr JA, Santer R, Tesarova M, Zeman J, Udd B, Taylor RW, Turnbull D, Hanna M, Fialho D, Suomalainen A, Zeviani M, Chinnery PF. Phenotypic spectrum associated with mutations of the mitochondrial polymerase &#x003b3; gene. <span><span class="ref-journal">Brain. </span>2006;<span class="ref-vol">129</span>:1674–84.</span> [<a href="/pubmed/16621917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16621917</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.hudson.2006.r244">Hudson G, Chinnery PF. Mitochondrial DNA polymerase-gamma and human disease. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:R244–52.</span> [<a href="/pubmed/16987890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16987890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.hunter.2011.311">Hunter MF, Peters H, Salemi R, Thorburn D, Mackay MT. Alpers syndrome with mutations in POLG: clinical and investigative features. <span><span class="ref-journal">Pediatr Neurol. </span>2011;<span class="ref-vol">45</span>:311–8.</span> [<a href="/pubmed/22000311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22000311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.huttenlocher.1976.186">Huttenlocher PR, Solitare GB, Adams G. Infantile diffuse cerebral degeneration with hepatic cirrhosis. <span><span class="ref-journal">Arch Neurol. </span>1976;<span class="ref-vol">33</span>:186–92.</span> [<a href="/pubmed/1252162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1252162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.kasiviswanathan.2009.19501">Kasiviswanathan R, Longley MJ, Chan SS, Copeland WC. Disease mutations in the human DNA polymerase thumb subdomain impart severe defects in mitochondrial DNA replication. <span><span class="ref-journal">J. Biol. Chem. </span>2009;<span class="ref-vol">284</span>:19501–10.</span> [<a href="/pmc/articles/PMC2740576/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2740576</span></a>] [<a href="/pubmed/19478085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19478085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.kelly.2000.170">Kelly DA. Liver transplantation: to do or not to do? <span><span class="ref-journal">Pediatr Transplant. </span>2000;<span class="ref-vol">4</span>:170–2.</span> [<a href="/pubmed/10933314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10933314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.lamantea.2002.211">Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, Papadimitriou A, Spelbrink H, Silvestri L, Casari G, Comi GP, Zeviani M. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. <span><span class="ref-journal">Ann Neurol. </span>2002;<span class="ref-vol">52</span>:211–9.</span> [<a href="/pubmed/12210792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12210792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.luoma.2004.875">Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, Oldfors A, Rautakorpi I, Peltonen L, Majamaa K, Somer H, Suomalainen A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">364</span>:875–82.</span> [<a href="/pubmed/15351195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15351195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.luoma.2005.1907">Luoma PT, Luo N, Loscher WN, Farr CL, Horvath R, Wanschitz J, Kiechl S, Kaguni LS, Suomalainen A. Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:1907–20.</span> [<a href="/pubmed/15917273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15917273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.lutz.2009.126">Lutz RE, Dimmock D, Schmitt ES, Zhang Q, Tang LY, Reyes C, Truemper E, McComb RD, Hernandez A, Basinger A, Wong LJ. De novo mutations in POLG presenting with acutre liver failure or encephalopathy. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2009;<span class="ref-vol">49</span>:126–9.</span> [<a href="/pubmed/19252446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19252446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.mameni_kien_.2017.74">Mameni&#x00161;kien&#x00117; R, Wolf P. Epilepsia partialis continua: a review. <span><span class="ref-journal">Seizure. </span>2017;<span class="ref-vol">44</span>:74–80.</span> [<a href="/pubmed/28029552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28029552</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.mancuso.2004.1777">Mancuso M, Filosto M, Oh SJ, DiMauro S. A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:1777–9.</span> [<a href="/pubmed/15534189" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15534189</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.mandel.2001.337">Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, Anbinder Y, Berkowitz D, Hartman C, Barak M, Eriksson S, Cohen N. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:337–41.</span> [<a href="/pubmed/11687800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11687800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.naess.2012.67">Naess K, Barbaro M, Bruhn H, Wibom R, Nennesmo I, Von Dobeln U, Larsson N-G, Nemeth A, Lesko N. A deletion in the POLG1 gene causing Alpers syndrome. <span><span class="ref-journal">JIMD Rep. </span>2012;<span class="ref-vol">4</span>:67–73.</span> [<a href="/pmc/articles/PMC3509876/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509876</span></a>] [<a href="/pubmed/23430898" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430898</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.naess.2009.484">Naess K, Freyer C, Bruhn H, Wibom R, Malm G, Nennesmo I, von D&#x000f6;beln U, Larsson N. MtDNA mutations are a common cause of severe disease phenotypes in children with Leigh syndrome. <span><span class="ref-journal">Biochimica et Biophysica Acta. </span>2009;<span class="ref-vol">1787</span>:484–90.</span> [<a href="/pubmed/19103152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19103152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.naviaux.2004.706">Naviaux RK, Nguyen KV. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:706–12.</span> [<a href="/pubmed/15122711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15122711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.nguyen.2005.1493">Nguyen KV, &#x000d8;stergaard E, Ravn SH, Balslev T, Danielsen ER, Vardag A, McKiernan PJ, Gray G, Naviaux RK. POLG mutations in Alpers syndrome. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:1493–5.</span> [<a href="/pubmed/16177225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16177225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.nguyen.2006.108">Nguyen KV, Sharief FS, Chan SS, Copeland WC, Naviaux RK. Molecular diagnosis of Alpers syndrome. <span><span class="ref-journal">J Hepatol. </span>2006;<span class="ref-vol">45</span>:108–16.</span> [<a href="/pubmed/16545482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16545482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.pagnamenta.2006.2467">Pagnamenta AT, Taanman JW, Wilson CJ, Anderson NE, Marotta R, Duncan AJ, Bitner-Glindzicz M, Taylor RW, Laskowski A, Thorburn DR, Rahman S. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma. <span><span class="ref-journal">Hum Reprod. </span>2006;<span class="ref-vol">21</span>:2467–73.</span> [<a href="/pubmed/16595552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16595552</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.parikh.2013.681">Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R., Mitochondrial Medicine Society Clinical Directors Working Group, Clinical Director's Work Group.  Practice patterns of mitochondrial disease physicians in North America. Part 2: treatment, care and management. <span><span class="ref-journal">Mitochondrion. </span>2013;<span class="ref-vol">13</span>:681–7.</span> [<a href="/pubmed/24063850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24063850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.parikh.2009.414">Parikh S, Saneto R, Falk MJ, Anslem I, Cohen BH, Haas R. A modern approach to the treatment of mitochondrial diseases. <span><span class="ref-journal">Curr Treat Options Neurol. </span>2009;<span class="ref-vol">11</span>:414–30.</span> [<a href="/pmc/articles/PMC3561461/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3561461</span></a>] [<a href="/pubmed/19891905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19891905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.ponamarev.2002.15225">Ponamarev MV, Longley MJ, Nguyen D, Kunkel TA, Copeland WC. Active site mutation in DNA polymerase &#x003b3; associated with progressive external ophthalmoplegia causes Error-prone DNA synthesis. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:15225–8.</span> [<a href="/pubmed/11897778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11897778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.rantam_ki.2007.532">Rantam&#x000e4;ki M, Luoma P, Virta JJ, Rinne JO, Raetau A, Suomalainen A, Udd B. Do carriers of POLG mutation W748S have disease manifestations? <span><span class="ref-journal">Clin Genet. </span>2007;<span class="ref-vol">72</span>:532–7.</span> [<a href="/pubmed/17894835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17894835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.rodriguez.2007.235">Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. <span><span class="ref-journal">Muscle Nerve. </span>2007;<span class="ref-vol">35</span>:235–42.</span> [<a href="/pubmed/17080429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17080429</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.rouzier.2014.542">Rouzier C, Chaussenot A, Serre V, Fragaki K, Bannwarth S, Ait-El-Mkadem S, Attarian S, Kaphan E, Cano A, Delmont E, Sacconi S, Mousson de Camaret B, Rio M, Lebre AS, Jardel C, Deschamps R, Richelme C, Pouget J, Chabrol B, Paquis-Flucklinger V. Quantitative multiplex PCR of short fluorescent fragments for the detection of large intragenic POLG rearrangements in a large French cohort. <span><span class="ref-journal">Eur J Hum Genet. </span>2014;<span class="ref-vol">22</span>:542–50.</span> [<a href="/pmc/articles/PMC3953900/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3953900</span></a>] [<a href="/pubmed/23921535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23921535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.saneto.2013.167">Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. <span><span class="ref-journal">Pediatr Neurol. </span>2013;<span class="ref-vol">48</span>:167–78.</span> [<a href="/pmc/articles/PMC3578656/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3578656</span></a>] [<a href="/pubmed/23419467" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419467</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.saneto.2010.140">Saneto RP, Lee I-C, Koenig MK, Bao X, Weng SW, Naviaux RK, Wong L-J. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. <span><span class="ref-journal">Seizure. </span>2010;<span class="ref-vol">19</span>:140–6.</span> [<a href="/pmc/articles/PMC3099441/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3099441</span></a>] [<a href="/pubmed/20138553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20138553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.smith.1996.235">Smith JK, Mah JK, Castillo M. Brain MR imaging findings in two patients with Alpers' syndrome. <span><span class="ref-journal">Clin Imaging. </span>1996;<span class="ref-vol">20</span>:235–7.</span> [<a href="/pubmed/8959359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8959359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.taanman.2009.248">Taanman JW, Rahman S, Pagnamenta AT, Morris AA, Bitner-Glindzicz M, Wolf NI, Leonard JV, Clayton PT, Schapira AH. Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:248–54.</span> [<a href="/pubmed/18828154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18828154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.tang.2012.862">Tang S, Dimberg EL, Milone M, Wong LJ. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations. <span><span class="ref-journal">J Neurol. </span>2012;<span class="ref-vol">259</span>:862–8.</span> [<a href="/pubmed/21993618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21993618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.tang.2011.669">Tang S, Wang J, Lee NC, Milone M, Halberg MC, Schmitt ES, Craigen WJ, Zhang W, Wong LJ. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:669–81.</span> [<a href="/pubmed/21880868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21880868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.tzoulis.2006.1685">Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, Ferrari G, Aarseth JH, Bindoff LA. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. <span><span class="ref-journal">Brain. </span>2006;<span class="ref-vol">129</span>:1685–92.</span> [<a href="/pubmed/16638794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16638794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.van_goethem.2001.211">Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">28</span>:211–2.</span> [<a href="/pubmed/11431686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11431686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.van_goethem.2003a.175">Van Goethem G, L&#x000f6;fgren A, Dermaut B, Ceuterick C, Martin JJ, Van Broeckhoven C. Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in POLG and C10orf2/Twinkle. <span><span class="ref-journal">Hum Mutat. </span>2003a;<span class="ref-vol">22</span>:175–6.</span> [<a href="/pubmed/12872260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12872260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.van_goethem.2004.1251">Van Goethem G, Luoma P, Rantam&#x000e4;ki M, Al Memar A, Kaakkola S, Hackman P, Krahe R, L&#x000f6;fgren A, Martin JJ, De Jonghe P, Suomalainen A, Udd B, Van Broeckhoven C. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">63</span>:1251–7.</span> [<a href="/pubmed/15477547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15477547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.van_goethem.2003b.133">Van Goethem G, Martin JJ, Dermaut B, L&#x000f6;fgren A, Wibail A, Ververken D, Tack P, Dehaene I, Van Zandijcke M, Moonen M, Ceuterick C, De Jonghe P, Van Broeckhoven C. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. <span><span class="ref-journal">Neuromuscul Disord. </span>2003b;<span class="ref-vol">13</span>:133–42.</span> [<a href="/pubmed/12565911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12565911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.visser.2011.218">Visser NA, Braun KP, Leijten FS, van Nieuwenhuizen O, Wokke JH, van den Bergh WM. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. <span><span class="ref-journal">J Neurol. </span>2011;<span class="ref-vol">258</span>:218–22.</span> [<a href="/pmc/articles/PMC3036811/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3036811</span></a>] [<a href="/pubmed/20803213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20803213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.winterthun.2005.1204">Winterthun S, Ferrari G, He L, Taylor RW, Zeviani M, Turnbull DM, Engelsen BA, Moen G, Bindoff LA. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:1204–8.</span> [<a href="/pubmed/15824347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15824347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.wolf.2005.441">Wolf B. Biotinidase: its role in biotinidase deficiency and biotin metabolism. <span><span class="ref-journal">J Nutr Biochem. </span>2005;<span class="ref-vol">16</span>:441–5.</span> [<a href="/pubmed/15992688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15992688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.wong.2008.e150">Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, Milone M, Cohen BH, Wical B, Ganesh J, Basinger AA, Burton BK, Swoboda K, Gilbert DL, Vanderver A, Saneto RP, Maranda B, Arnold G, Abdenur JE, Waters PJ, Copeland WC. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:E150–E172.</span> [<a href="/pmc/articles/PMC2891192/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2891192</span></a>] [<a href="/pubmed/18546365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18546365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.w_rle.1998.63">W&#x000f6;rle H, Kohler B, Schlote W, Winkler P, Bastanier CK. Progressive cerebral degeneration of childhood with liver disease (Alpers-Huttenlocher disease) with cytochrome oxidase deficiency presenting with epilepsia partialis continua as the first clinical manifestation. <span><span class="ref-journal">Clin Neuropathol. </span>1998;<span class="ref-vol">17</span>:63–8.</span> [<a href="/pubmed/9561326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9561326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alpers.REF.zhou.2018.750">Zhou Q, Lin Y, Ye J, Li L, Hu N, Wang D, Wang Y. Homozygous TBC1D24 mutations in a case of epilepsia partialis continua. <span><span class="ref-journal">Front Neurol. </span>2018;<span class="ref-vol">8</span>:750.</span> [<a href="/pmc/articles/PMC5787533/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5787533</span></a>] [<a href="/pubmed/29416524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29416524</span></a>]</div></li></ul></div></div><div id="alpers.Chapter_Notes"><h2 id="_alpers_Chapter_Notes_">Chapter Notes</h2><div id="alpers.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>1 March 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 December 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 October 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 March 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>9 December 2007 (bhc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK26471</span><span class="label">PMID: <a href="/pubmed/20301791" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301791</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pnpla6-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pol3-leuk/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK26471&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK26471/?report=reader">PubReader</a></li><li><a href="/books/NBK26471/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK26471" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK26471" style="display:none" title="Cite this Page"><div class="bk_tt">Cohen BH, Chinnery PF, Copeland WC. POLG-Related Disorders. 2010 Mar 16 [Updated 2018 Mar 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK26471/pdf/Bookshelf_NBK26471.pdf">PDF version of this page</a> (581K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#alpers.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#alpers.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#alpers.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#alpers.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#alpers.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#alpers.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#alpers.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#alpers.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#alpers.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#alpers.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#alpers.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#alpers.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=56652[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TWNK</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5428[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">POLG</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK26471+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1953482" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1953482" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1953482" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1953482" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24741716" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RRM2B</i>-Related Mitochondrial Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RRM2B</i>-Related Mitochondrial Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gorman GS, Taylor RW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301403" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mitochondrial Disorders Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mitochondrial Disorders Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chinnery PF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28480171" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Pathogenicity in POLG syndromes: DNA polymerase gamma pathogenicity prediction server and database.</a><span class="source">[BBA Clin. 2017]</span><div class="brieflinkpop offscreen_noflow">Pathogenicity in POLG syndromes: DNA polymerase gamma pathogenicity prediction server and database.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nurminen A, Farnum GA, Kaguni LS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BBA Clin. 2017 Jun; 7:147-156. Epub 2017 Apr 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18546365" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Molecular and clinical genetics of mitochondrial diseases due to POLG mutations.</a><span class="source">[Hum Mutat. 2008]</span><div class="brieflinkpop offscreen_noflow">Molecular and clinical genetics of mitochondrial diseases due to POLG mutations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, Milone M, Cohen BH, Wical B, Ganesh J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mutat. 2008 Sep; 29(9):E150-72. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301791" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301791" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04105139a66ee2ba9156cf">POLG-Related Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">POLG-Related Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:43:45-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE8838E8E04032A100000000057F01E9&amp;ncbi_session=CE8838E8E0410501_1407SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK26471%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK26471&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK26471/&amp;ncbi_pagename=POLG-Related Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8838E8E0410501_1407SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>